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Abstract 
Objective- To evaluate the use of a topical ophthalmic steroid (1% prednisolone acetate) 
and non-steroidal anti-inflammatory drug (0.1% diclofenac) on blood glucose concentrations, 
serum fructosamine concentrations, and clinical scores in diabetic dogs with cataracts using 
descriptive analysis.   
Animals- Twelve client-owned dogs with naturally-occurring, controlled (per history and 
physical examination), insulin-treated diabetes mellitus and cataract.  A total of 40 dogs will be 
enrolled in the study, as determined by power analysis. 
Procedures- This was a prospective, randomized, double-masked, experimental study 
with 2 phases of data collection.  Dogs were enrolled from October 2011 to March 2014 and 
were assigned to 1 of 2 treatments (Drug Red or Drug Blue) using blocked randomization; dogs 
received either 1% prednisolone acetate suspension or 0.1% diclofenac solution.  Patient history, 
physical, and ophthalmic examinations were performed and a clinical score assigned at 
enrollment (Phase 1 [day 0]) and upon return (Phase 2 [day 32]).  At these times, a complete 
blood count, serum chemistry, urinalysis, and serum fructosamine concentration were performed 
prior to hospitalization for up to 72 hours for continuous glucose monitoring.  For 4 weeks (day 3 
to 31), dogs returned home, and owners administered the dispensed ophthalmic medication 4 
times daily to both eyes. Descriptive analysis of data was performed; statistical analysis will 
follow enrollment of 40 dogs. 
Results- Twelve dogs have completed the study, with 6 dogs assigned to each treatment 
group. Dogs received 4.44 or 0.44 mg/day of prednisolone acetate or diclofenac, respectively.  
Dogs assigned to Drug Red more commonly exhibited elevations in serum liver enzyme activity.  
Drug Red group showed a greater percent increase in fructosamine concentrations over time.  
  
Based on glucose curves alone (22 curves analyzed), an insulin dose increase was recommended 
for 12 curves.  An insulin dose decrease and no dose change were recommended for 5 curves 
each. During treatment, 1 dog reportedly developed polyuria and polydipsia.   
Conclusions- Descriptive analysis revealed differences in some outcomes of interest 
among dogs treated with 2 different ophthalmic anti-inflammatory medications.  Data collection 
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Chapter 1 - Literature Review  
 Diabetes Mellitus 
 Background 
Diabetes mellitus (DM) is the most common disorder of the endocrine pancreas in dogs and is 
characterized by an absolute or relative insulin deficiency leading to persistent hyperglycemia 
and glucosuria.[1]  Insulin plays an integral role in the body’s ability to appropriately metabolize 
carbohydrates, fatty acids, and amino acids.  Lacking sufficient insulin leads to “cellular 
starvation” due to inappropriate carbohydrate absorption and utilization necessitating the 
formation of alternate energy sources via catabolism of stored fat and protein.  Insulin deficiency 
places an individual at risk for electrolyte imbalance, dehydration, and at a higher risk of 
secondary infection facilitated by an elevated concentration of circulating glucose.[1, 2]  
Polyuria (PU) and polydipsia (PD) with concurrent weight loss lend suspicion to the diagnosis, 
which is confirmed by simultaneous elevations in blood and urine glucose concentrations.  A 
substantial commitment is involved in the treatment of canine DM and management of 
concurrent disease conditions.   
 
 Incidence and Signalment 
Diabetes mellitus is a common endocrinopathy in dogs, with reported prevalence ranging from 1 
in 100 to 1 in 500 dogs affected.[3] The Veterinary Medical Database
a
 showed the incidence of 
DM in dogs to increase by greater than threefold from 1970 to 1999.[4]  Increase in reported 
incidence may be attributed to greater awareness and/or willingness of owners to have dogs 
evaluated at a referral institution as opposed to DM truly becoming more common.  Age of onset 
is typically 7-9 years, and female dogs are reported to be affected approximately twice as often 
as male dogs.[1, 2, 5] 
 
Some breeds reported to have an increased risk for developing DM include the Australian 
Terrier, Standard and Miniature Schnauzer, Bichon Frise, Finnish Spitz, Fox Terrier, Miniature 
Poodle, Samoyed, Cairn Terrier, Keeshond, Maltese, Siberian Husky, Toy Poodle, Lhasa Apso, 
and Yorkshire Terrier, listed in order of descending odds ratio according to one large 
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retrospective study.[4]  Smaller breeds of dogs were shown to be at increased risk of developing 
DM.[4] 
 
 Etiology of DM 
The etiology of disease development is believed to be multi-factorial, involving immune-
mediated destruction of the endocrine pancreas or destruction of the pancreas secondary to 
inflammation.[6] Body condition and diet play a role, along with environmental factors,[7] 
insulin antagonistic diseases (such as other endocrinopathies, renal insufficiency, hyperlipidemia, 
and cardiac disease), infection, glucocorticoids, and possibly a genetic predisposition.[1, 4, 8]  
Breed, preexisting hyperadrenocorticism (HAC or Cushing’s disease), and female gender were 
identified via multivariate analysis as risk factors for development of DM.[5] 
 
Inflammation of the pancreas can cause its progressive destruction, resulting in dysfunction of 
the exocrine and endocrine components and subsequent disease.  Chronic pancreatitis can 
damage the pancreatic islets (the hormone secreting cells of the pancreas), leading to the 
eventual development of insulin deficiency and DM.[9] Approximately 28% to 36% of dogs 
have been reported to develop DM secondary to chronic pancreatitis.[6, 7] Additionally, 
pancreatectomized dogs represent a reliable experimental model for canine DM.[10]  
 
A genetic predisposition to canine DM has been suggested;[7, 8] however, the mode of 
inheritance and specific genes involved have not been identified in most breeds.  Regional 
differences in breeds over-represented for DM may relate to popularity of particular breeds in 
diverse geographical locations or variations in gene pools.[8] Certain genes (human leukocyte 
antigen genes) have been linked to DM in humans. Canine gene analogs (dog leukocyte antigen 
genes) are associated with an increased risk of DM in dogs.[4, 8, 11]  This tendency, along with 
the fact that several of these genes appear to be breed-specific, suggests that genetics are 
involved in development of the disease.[8] Documentation of genetic-based DM is scarce with a 
report of familial inheritance in five Samoyeds,[12] familial predisposition in miniature 




 Anatomy and Physiology of Glucose Metabolism 
Following a meal, glucose and other nutrients are absorbed through the gastrointestinal tract into 
the blood stream.  Insulin is required for utilization of glucose for energy.  Physiologic 
hyperglycemia is detected via perfusion of blood through the pancreatic islets of Langerhans.  
Pancreatic islets are islands of endocrine tissue located within the pancreatic parenchyma and are 
composed of four major cell types with roles in hormone secretion: α, β, δ, and F cells.[1] Insulin 
is secreted into the blood stream by the centrally located β cells.  In order to accommodate 
cellular energy demands, insulin facilitates glucose transport into cells of organs and muscles 
following activation of a cell membrane receptor protein.  The four subunit receptor requires that 
insulin binds to the two external α subunits to cause autophosphorylation of the two internal β 
subunits leading to activation of tyrosine kinase.  An intracellular cascade is activated that allows 
cellular uptake of nutrients and subsequent metabolism.[15] 
 
The primary function of insulin is to initiate anabolic reactions involving carbohydrates, nucleic 
acids, and lipids. Insulin enhances glucose oxidation and formation of glycogen, while also 
stimulating lipogenesis.[2] Glucose is utilized via cellular aerobic and anaerobic metabolism to 
ultimately form utilizable energy in the form of adenosine-5’ triphosphate (ATP).  When glucose 
is transported into the cell via mobilized transporter proteins (GLUT proteins), it is 
phosphorylated for use either through glycolysis or the citric acid cycle, stored as glycogen in the 
liver and muscles, or converted to fat and stored in adipose tissue.[15] 
 
Insulin and glucagon act in concert to maintain glucose homeostasis but have very different 
roles.[2] During times of hypoglycemia, glucagon is secreted from α cells of the pancreas, which 
are immediately adjacent to the insulin-producing β cells.  Glycogenolysis, gluconeogenesis, and 
lipolysis, all of which are influenced by glucagon, ensue to maintain a circulating energy 
source.[15] 
 
 Pathophysiology of Absolute or Relative Insulin Deficiency  
Absolute insulin deficiency (Type I) is defined as an insufficient quantity of insulin produced by 
the body.  The body’s poor ability to detect insulin and respond appropriately is known as 
relative insulin deficiency (Type II); Types I and II both create inappropriately low tissue 
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glucose levels and resultant hyperglycemia.[1] These two disease conditions are also referred to 
as immune-mediated DM (Type 1) and insulin resistant DM (Type 2).  Dogs affected by DM are 
considered to have Type I, immune-mediated DM.[1, 8] 
 
 Clinical Signs in Dogs  
Four hallmark clinical signs of DM in dogs include PU, PD, PP, and weight loss.[1] Glucose 
absorption into the “satiety center” of the hypothalamus is required to suppress the adjacent 
“hunger center” and curb an individual’s appetite.  Passage into this region of the brain is 
mediated by insulin; in the face of relative or absolute insulin deficiency, the satiety center is not 
inhibited, leading to PP.[1] 
 
Despite elevated circulating blood glucose (BG), the cells of the body are, in effect, “starved” for 
energy.  Poor utilization of ingested glucose leads to weight loss.  Insulin is a powerful inhibitor 
of lipolysis.  In the absence of insulin, fat mobilization and muscle atrophy occur, contributing to 
weight loss and decline in body condition.[15] 
 
Glucose is not present in the urine of dogs in physiologically normal conditions.  Although it is 
freely filtered from plasma by the glomeruli, it is completely reabsorbed from the proximal renal 
tubules via secondary active transport.[16] When the transport maximum is exceeded, that is, 
when the filtered load exceeds the rate at which the tubules are capable of complete glucose 
reabsorption from the ultra-filtrate, glucose appears in the urine.[16] The glucose renal threshold 
is 180-220 mg/dL in dogs, meaning that persistent BG concentrations above this threshold can 
lead to glucosuria.[1]  Glucose measures 180 Daltons in size compared to water’s 18 
Daltons.[16]  Due to its relatively large molecular size, an osmotic gradient is created.  Water is 
drawn into the tubules leading to increased urine volume, dilute urine, and the potential for 
dehydration due to excessive loss of water.  The increased volume of urine causes diabetic dogs 






 Diagnosis and Additional Diagnostic Test Abnormalities 
Dogs are diagnosed with DM after documenting persistent, fasting hyperglycemia and 
glucosuria.  Aside from sometimes profound hyperglycemia, additional blood work 
abnormalities are commonly seen in diabetic dogs.  Serum biochemical analysis may reveal 
hepatic enzyme elevations of alkaline phosphatase (ALP), alanine transaminase P5P (ALT), or 
both.  An elevated ALP has been reported to be a more common finding compared to an elevated 
ALT in insulin-treated diabetic dogs with persistent clinical signs of DM.[17] Diabetic dogs 
often show electrolyte derangements either related to altered renal tubule physiology with 
glucose retention or due to varying degrees of dehydration.  Hypercholesterolemia and/or 
hypertriglyceridemia are common findings.[1, 17] While complete blood counts are usually 
unremarkable, a stress leukogram may be observed.[15] 
 
Urinalysis may reveal dilute urine due to an osmotic gradient created by glucosuria.  Proteinuria 
and bacteriuria are also somewhat common findings in diabetic dogs, as a glucosuric 
environment and lower urine specific gravity support bacterial growth.[1]  Ketonuria may 
additionally be present. Ketones are an alternative energy source for most tissues of the body, 
produced under conditions of nutritional stress, such as starvation or insulin deficiency.  Adipose 
tissue is catabolized and metabolites distributed to the blood stream.  Hepatocytes are responsible 
for ketone production; ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) are 
derived from oxidation of free fatty acids. While detection in the blood is possible, this is rarely 
performed in veterinary medicine; the degree of ketonemia is interpreted indirectly by 
documenting worsening of metabolic acidosis.[1] When ketones are formed but underutilized, 
ketone bodies spill into the urine (similarly to glucose) and may contribute to the osmotic 
gradient in urine. In dogs, identification of ketonuria is performed through the use of urine test 
strips.[1, 18] 
 
 Treatment of DM in Dogs 
Treatment goals are directed at achieving remission of the classic clinical signs noted by owners 
- PP, PU, PD, weight loss and minimizing complications of the unregulated diabetic state such as 
secondary infection or diabetic ketoacidosis (DKA).  Improvement in clinical signs is attained by 
lowering BG.  As dogs are usually insulin dependent when DM is diagnosed,[1] exogenous 
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insulin is needed to improve hyperglycemia and nutrient utilization.  There are several insulin 
options with various durations of activity, classified as either rapid-acting (Lispro, Aspart, and 
Glulisine, which are not commonly used in veterinary medicine), short-acting (regular), 
intermediate-acting (neutral protamine Hagedorn [NPH] and porcine lente [purified porcine zinc 
insulin suspension]), or long-acting insulin (Glargine, Detemir, and human recombinant 
protamine zinc insulin [PZI]).  Porcine lente is the only insulin approved by the Food and Drug 
Administration for use in dogs.[18] The standard of initial therapy for dogs that are stable (not in 
DKA) and have a normal appetite is an intermediate-acting insulin administered subcutaneously 
twice daily.  Recommended administration is at approximately 12 hour intervals, following a full 
meal. Empirical doses are recommended initially based on a fraction of lean body weight (BW) 
(typically 0.5 units per kilogram of BW) and are titrated up according to BG testing and/or 
persistent clinical signs of PU, PD, and PP.[18] Owners are educated on how to handle insulin 
and administer subcutaneous injections; it is advisable to monitor while the owner prepares and 
administers the first dose.  Most dogs considered well-controlled receive an insulin dose within a 
dosing range of 0.2 to 1.0 unit/kg every 12 hours.[19]  Uncontrolled dogs or dogs requiring a 
higher dose of insulin (> 1.5 units/kg) should be evaluated for insulin resistance.[18] 
 
If the dog is fed a commercial diet, recommending the ideal amount of food to offer to maintain 
or achieve an ideal BW may be necessary; continuing the dog’s original diet twice daily is 
preferred to prevent loss of appetite during diet transition or the need to recalculate the insulin 
dose based on a new diet.  Once diet and insulin dose are established, feedings must follow a 
consistent schedule, quantity, and diet type to best maintain glycemic control.[1, 18] When an 
adjustment in diet is indicated,  dog food low in simple carbohydrates and high in protein and 
soluble and insoluble fiber is reported to minimize postprandial hyperglycemia.[18]  Diets 
designed for weight management or weight loss may also be good selections for the overweight 




 Complications Associated with DM 
 Ocular Complications 
Cataracts are one of the most common ophthalmic complications of DM in dogs.[1]  Aqueous 
humor resembles an ultra-filtrate of plasma, composed of many organic (i.e., glucose, amino 
acids, lactate, protein, etc.) and inorganic (i.e., bicarbonate, sodium, chloride, oxygen, etc.) 
compounds. Passage of these compounds through the lens capsule occurs via passive diffusion or 
through active transport. (Appendix A)  The energy source for the lens is glucose, which diffuses 
from the aqueous humor through the semi-permeable lens capsule or is transported via a glucose 
transporter (GLUT-1), found within the lens epithelial cells.[20-22]  Energy is primarily derived 
from anaerobic glycolysis (Embden-Meyerhof pathway) with the rate of glycolysis being 
controlled by the amount of hexokinase enzyme and the rate of entrance of glucose through the 
lens capsule.  In a hyperglycemic state, lens glucose metabolism is altered.  The concentration of 
glucose-6-phosphate is increased, saturating the hexokinase enzyme and inhibiting 
glycolysis;[22, 23] a greater concentration of glucose is shunted to an alternate pathway where 
glucose is converted to sorbitol.[20, 24]  The osmotic gradient formed from an excessive sorbitol 
concentration results in imbibition of water with subsequent swelling and rupture (hydropic 
degeneration) of the lens fibers, leading to cataract formation.[25, 26] 
 
Diabetic retinopathy occurs in both canine and human diabetic patients.[27-30] Persistent 
hyperglycemia leads to capillary basement membrane thickening, collagen and fibronectin 
deposition in the extracellular matrix, and loss of pericytes.[27] Retinal blood vessels of diabetic 
patients display fragility, which may be manifested funduscopically as intraretinal or preretinal 
hemorrhages or microaneurysms, termed diabetic retinopathy.  This finding is commonly 
recognized in humans[27] but was documented to occur in 20 and 21% of dogs in two 
reports.[29, 31]  In  a galactosemic canine model of DM, 10 juvenile Beagles that were 
unilaterally aphakic developed microaneurysms, retinal hemorrhages, and other vascular 
pathology by 28 months after starting a 30% galactose diet; progression of retinal pathology was 
also documented with fluorescein angiography and monitored for 41 months while on this 
diet.[32]  Retinal thinning, either focally or diffusely, may also be noted as a component of 
diabetic retinopathy.[29]   
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Other ocular complications reported to occur with DM in dogs include: keratoconjunctivitis 
sicca,[33, 34] reduced corneal sensitivity (independent of glycemic control or duration of 
DM),[34, 35] conjunctival epithelial dysplasia, reduced goblet cell densities, significantly 
reduced tear film break up times,[34] and endothelial degeneration manifested by polymegethism 
and pleomorphism.[36]  The etiopathogeneses for the development of each of these conditions 
have not been confirmed. Some anatomical changes show direct relationship with degree of 
diabetic control in both dogs and humans.[25, 27, 30, 36] 
 
Two of the leading causes of blindness in humans in the United States are consequences of 
ocular disease associated with DM.  These include proliferative diabetic retinopathy and diabetic 
macular degeneration, which often occur concurrently.  Diabetic retinopathy in humans is 
subdivided into proliferative and non-proliferative forms,[27, 30] and together, they account for 
12% of new cases of blindness each year.[27] Microaneurysms, intraretinal hemorrhages, venous 
looping, and intraretinal microvascular abnormalities typify the non-proliferative form.  
Proliferative diabetic retinopathy, which is the more severe form, is characterized by 
neovascularization on or adjacent to the optic disc or in the vitreous or presence of 
vitreal/preretinal hemorrhage.  New vessel growth occurs as a result of retinal ischemia, but these 
vessels are often fragile and lead to vitreal hemorrhage.  Diabetic macular degeneration can 
occur with any level of severity of diabetic retinopathy; it involves vascular leakage and edema 
causing thickening of the retina with deposition of hard exudates (accumulations of lipid and 
serum), adjacent to or involving in the cone-rich macula, which obscures retinal function and 
visual acuity.[27] Diagnosis may require fluorescein angiography, optical coherence 
tomography, or ultrasonography in cases where the fundus is poorly visualized.  Proliferative or 
fragile vasculature may require laser photocoagulation (panretinal or grid/focal) in order to 
reduce the risk of vitreal hemorrhage and retinal detachment, and vitreal hemorrhage can be 
removed by pars plana vitrectomy.  Glycemic and blood pressure control, along with eating a 
low fat diet and eliminating smoking help delay development of or prevent exacerbation of 
diabetic retinopathy.[27, 30]  Severe complications of diabetic retinopathy include traction 





 Heightened Susceptibility to Infection  
Diabetic dogs often experience chronic or recurrent infections due to a diminished resistance to 
infection.[2] The innate inflammatory response to bacterial pathogen-associated molecular 
patterns in these dogs is altered, as pro-inflammatory cytokine (TNF, IL-6, and IL-10) 
production is increased without a corresponding and equivalent anti-inflammatory cytokine 
production.[37] This potentially explains a diabetic dog’s increased susceptibility to 
inflammation and infection. Affected dogs also experience impaired chemotactic, phagocytic, 
and microbiocidal functions of leukocytes.[2]  Urinary tract infections are a common 
complication seen in unregulated diabetic dogs.[38]  The urine can be more dilute and saturated 
with glucose, favoring presence and growth of glucose-fermenting bacteria such as Escherichia 
coli, Proteus species, and Aerobacter aerogenes.[2] Retrospective studies report, 21-24% of 
diabetic dogs evaluated had an occult urinary tract infection with bacteriuria that was not always 
accompanied by pyuria. Escherichia coli was the most common bacteria isolated from the urine. 
[17, 38] Bacterial infections can contribute to insulin resistance.[17, 19] 
 
 Other Complications 
Hepatomegaly occurs in diabetic dogs due to chronic, inappropriate fat deposition and hepatic 
parenchymal remodeling.[2]  Hepatomegaly was documented in 61% of diabetic dogs, in a 
retrospective study.[17] Systemic hypertension and urine protein loss are relatively common 
findings in diabetic dogs.[39]  In a prospective, observational study of 11 diabetic dogs with 
evaluation over 2 years, 55% were diagnosed with systolic hypertension (defined as blood 
pressure >150mmHg) and 64% were diagnosed with diastolic hypertension (defined as blood 
pressure>95mmHg).[31] Also, microalbuminuria and elevated urine protein:creatinine ratio were 
documented in up to 73% and 55% of dogs, respectively.  No significant association between 
these vascular complications and time since diagnosis of DM or degree of BG control was 
found.[31] Diabetic ketoacidosis is a possible complication of chronic insulin deficiency, as 
ketones are produced as an alternate energy source.  Excessive circulating levels of ketones alter 
acid-base balance (leading to decreased total carbon dioxide and a high anion gap metabolic 
acidosis), contribute to alterations in electrolytes, and encourage dehydration, making this 
condition a medical emergency depending on the severity of clinical signs.[1, 18] Peripheral 
neuropathy[1, 40] and the presence of a concurrent endocrinopathy, primarily HAC,[1] are 
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additional possible sequela associated with DM.  The clinical signs and physical exam (PE) 
findings of both DM and HAC have considerable overlap, sometimes making diagnosis of 
concurrent HAC a challenge in known diabetic dogs.[41, 42]  In a retrospective study of 221 
diabetic dogs, HAC was diagnosed in 23%.[17] 
 
 Glycemic Control 
 Evaluation of Glycemic Control 
Evaluation of glycemic control in diabetic dogs is challenging, with no consistent 
recommendations in the literature outlining a specific diagnostic testing protocol, nor an 
available test able to yield a definitive yes (well regulated) or no (poorly regulated) answer.[1] 
Evaluation of the degree of BG regulation is based on interpretation of a compilation of tests, 
which may include any or several of the following: a glucose curve (currently the gold standard 
of glycemic testing), urine glucose and ketone concentration monitoring, serum fructosamine 
and/or glycated hemoglobin concentrations, and determination of interstitial glucose 
concentrations using a continuous glucose monitoring system.  History and PE findings are 
highly valuable in determining of degree of DM control.[43] 
 
Despite being considered the gold standard of testing, glucose curves are affected by stress, the 
amount and timing of food consumed, inherent error when measuring insulin doses in a syringe, 
the variability in the rate and amount of insulin absorbed from the injection site,[44] and the 
inaccuracy of handheld glucometers.[45]  A study comparing whole BG using a handheld 
glucometer to serum glucose using the laboratory plasma hexokinase method reported 
glucometers to slightly underestimate circulating blood glucose with the concentration typically 
measuring 2 mmol/L lower with glucometers; this is not a clinically important discrepancy for 
most scenarios.[45]  
 
A recent study demonstrated that there is a large day-to-day variation in BG concentrations 
causing a single diabetic dog to have very different BG curves over subsequent days with no 
changes in therapy.[44]  Although serial BG curves have limitations as a clinical tool in diabetic 
dogs, they remain a useful test for evaluating glycemic control in this species.[44] 
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Fructosamines are stable ketoamine compounds formed by the irreversible, insulin-independent 
binding of glucose to an amino group on serum proteins.  The concentration of fructosamine 
reflects the average BG concentration over the preceding one to three weeks.[46]  Fructosamine 
concentrations are not affected by day-to-day variations that affect serial BG concentrations.  
The test has a high sensitivity and specificity (93% and 95%, respectively, according to one 
study)[47] and may be chosen as a screening test for initial diagnosis, as well as a method of 
assessing glycemic control, in diabetic dogs.[46, 47]  Correction of the fructosamine 
concentration for various serum proteins is not recommended, as there was no difference 
between corrected and uncorrected concentrations in discriminating between dogs with and 
without DM.[47] Well-controlled diabetic dogs show significantly lower fructosamine 
concentrations on average compared to poorly controlled diabetic dogs.[43] However, 
hypoalbuminemia, hyperlipidemia, and azotemia can affect serum fructosamine concentrations 
in healthy dogs,[48] and presumably in diabetic dogs, as well.  Glycated hemoglobin 
concentration measures glucose bound to hemoglobin and is therefore representative of the 
average BG concentration over the previous six to eight weeks.  Fructosamine estimation is more 




 continuous glucose monitoring system
b 
estimates glucose concentrations by 
converting interstitial glucose into gluconic acid and hydrogen peroxide through a reaction that 
creates an electric current.  The Guardian unit uses proprietary algorithms to convert the signal 
into a numeric value representative of glucose concentration.  The use of a continuous glucose 
monitoring system to measure glucose concentration alleviates the need for repeated 
venipunctures, minimizes stress associated with repetitive glucose testing,[49] and provides 
considerably more information than that obtained with a standard BG curve.[50] The use of the 
Guardian monitoring system has been validated for use in veterinary medicine; it was found to 
correlate well with whole BG concentrations in clinically normal dogs.[49] Limitations of the 
system include the need to calibrate the system multiple times in a 24 hour period and a limited 






 Insulin Resistance 
When hyperglycemia is controlled, clinical signs of PU, PD, weight loss, and PP improve or 
subside.  Return of these clinical signs indicates a loss of glycemic control, which may be 
explained by insulin resistance.  Insulin resistance occurs when there is a subnormal biologic 
response and decreased tissue responsiveness to endogenously produced or exogenously 
administered insulin.  It is suspected in diabetic dogs when a dog is given >1.5 units/kg per dose 
of insulin.[19] Conditions that most commonly cause insulin resistance in dogs include the 
following: treatment with diabetogenic drugs (glucocorticoids), oral infections or urinary tract 
infections, severe obesity, HAC, diestrus, renal insufficiency, chronic pancreatitis, 
hyperlipidemia, neoplasia, and the development of insulin antibodies.[1, 7, 17, 38, 42]     
 
Glucocorticoids, whether endogenously released (stress-induced, HAC) or exogenously 
administered, exacerbate hyperglycemia by stimulating gluconeogenesis in the liver.  Not only is 
glucose production increased, but relative insulin resistance also ensues.[1]  Insulin antagonism 
occurs as a result of a decreased quantity of cell membrane insulin receptors, altered insulin 
receptor binding affinity, or impairment in a post-receptor step involving activation of the 
glucose transport system.[1] Pituitary-dependent HAC leads to decreased  function of pancreatic 
β cells and causes insulin resistance and hyperglycemia.  Having HAC places dogs at a 13 times 
greater risk of developing DM. Approximately 10% of dogs with HAC develop DM.[41] 
Similarly, systemic administration of steroids to diabetic dogs increases the insulin requirement.  
Systemic glucocorticoid administration is, therefore, considered “relatively contraindicated,” [1] 




A cataract is an opacity within the lens that forms due to alterations in the intralenticular 
metabolic environment.  Decreased activity of lens epithelial Na-K ATPase pumps causes 
alterations in electrolyte concentrations.  Oxygen consumption and ATP production decrease, 
and antioxidant activity is diminished;[20, 22] free radicals and reactive oxygen species are 
elaborated from damaged intracellular organelles, perpetuating damage to lens fibers and lysis of 
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fibers.[25]  The opacity develops due to a shift in concentration of lens proteins from soluble 
(crystalline) to insoluble, high-molecular weight proteins (albuminoids), which normally account 
for only approximately 15% of the lens protein.[20] 
 
 Classification of Cataracts 
Cataracts are classified into 4 stages by the amount of the lens that is affected.  Incipient 
cataracts occupy from 1-15% of the lens volume.  Immature cataracts account for all opacities 
with 15-99% affected lens volume. In mature cataracts, 100% of the lens is affected, and the 
animal is blind.  Hypermature cataracts are characterized by loss of lens volume, as degradation 
of lens proteins into amino acids and polypeptides creates small byproducts that diffuse through 
the intact lens capsule along with water.[20, 25]  Some dogs merely develop focal lenticular 
opacities that never progress to a more advanced stage; however, dogs may experience all stages 
of cataract with inconsistent rate of progression to each stage.  Lenses of diabetic dogs, due to 
the osmotic force created by sorbitol within the lens capsule, imbibe water and can quickly loose 
transparency secondary to hydropic degeneration.  Lenses may develop a “swollen” appearance, 
termed intumescence.  This type of cataract is diagnosed by the presence of a subjectively 
shallow anterior chamber caused by enlargement of the lens and anterior displacement of the iris 
diaphragm.  A potential side effect of an intumescent cataract is ocular hypertension. The 
pathway of aqueous humor flow from the posterior chamber through the pupil can be 
compromised by the swollen lens causing buildup of fluid in the posterior chamber and elevation 
of the intraocular pressure.  Lens capsule rupture may also occur with rapid lens 
intumescence.[20, 33] Spontaneous lens capsule rupture in non-diabetic patients is poorly 
documented in the literature but has been observed.[20] Hypermature cataracts, rapidly 
progressing cataracts, and lenses with capsular ruptures and have been shown to more frequently 




Cataract development in the dog can occur secondary to advanced age, ocular disease or 
inflammation, embryologic developmental issues leading to congenital cataracts, direct trauma, 
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toxic ocular environments (i.e., progressive retinal atrophy or other types of retinal 
degeneration), various medications (i.e., chronic ketaconazole administration[55]), 
electrocution,[56] radiation, inappropriate nutrition (amino acid imbalance) during early life, or 
systemic disease processes (i.e., DM, hypoparathyroidism), however, an inherited etiology is the 
most common cause in this species.[20] The severity of visual compromise depends on the 
location and degree of the lenticular opacity.  Cataracts are a common complication of DM in 
dogs.  Cataracts in diabetic dogs typically begin at the equator of the lens as vacuoles within the 
cortex[20, 24, 26] that may progress to 100% involvement of the lens material, resulting in 
blindness. The rate of cataract formation depends on the degree and duration of hyperglycemia, 
lenticular aldose reductase activity, degree of oxidative stress and free radical formation, and 
sorbitol concentration within the lens.[25, 57-60] A study evaluating 200 insulin-treated, diabetic 
dogs (degree of regulation not specified) showed 50% of dogs developed cataracts by 170 days 
following the diagnosis of DM, 75% by 370 days post diagnosis, and 80% by 470 days post 
diagnosis.[23] 
 
 Pathophysiology of Cataract Development Secondary to Hyperglycemia 
Glucose diffuses passively through the semi-permeable lens capsule or via facilitated 
transport.[20, 22]  Two glucose transporters have been identified in the lenses of rats; GLUT-1 is 
primarily present in the lens epithelial cells, while GLUT-3 was the predominant isoform in the 
lens fibers.[21]  Energy in the lens is primarily derived from anaerobic metabolism through the 
glycolytic or Embden-Meyerhof pathway with approximately 5% of glucose being processed 
through the sorbitol (also known as polyol) pathway.(Appendix A)  In a hyperglycemic state, 
lens glucose metabolism is altered in effort to prevent excessive lactic acid production and due to 
saturation of the hexokinase enzyme;[22, 23] a greater concentration of glucose (10-33%) is 
shunted to the sorbitol pathway for metabolism.[20, 24] Glucose is converted to sorbitol (or in 
the induced galactosemic model of cataract development, galactose to dulcitol) in a reaction 
catalyzed by aldose reductase.  Sorbitol is subsequently converted by sorbitol dehydrogenase to 
fructose,[2] which is able to slowly diffuse through the lens capsule or reenter the glycolytic 
pathway for further metabolism.[25]  Dulcitol is not further metabolized, causing more rapid 
cataract formation compared to that caused by sorbitol.[61] PubChem Compound Database
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documents sorbitol and dulcitol to have a similar molecular weight of approximately 182 
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Daltons, which is only slightly larger than that of glucose (180 Daltons).[15]  The polar character 
of sorbitol prevents efficient diffusion back through the lens capsule.  This, along with the fact 
that sorbitol is produced faster than it can be converted to fructose, causes accumulation of 
sorbitol.[25]  An osmotic gradient is formed from a high sorbitol concentration resulting in 
imbibition of water with subsequent swelling and rupture (hydropic degeneration) of the lens 
fibers.[25, 26]  Disruption of lenticular fibers, formation of interfibrillar clefts, changes in cell 
membrane permeability, oxidative damage, nonenzymatic glycosolation of lens crystallins, and 
generation of free radicals and reactive oxygen species all contribute to cataract formation.[2, 20, 
25, 57]  
 
The rate of cataract development is variable and is believed to be multifactorial dependent on 
individual aldose reductase activity, the dog’s degree of and duration of hyperglycemia, and the 
dog’s age.[23, 33, 62] Cataracts may be reversible in young diabetic humans with improvement 
of diabetic control.[25] Aldose reductase activity decreases with increasing age in dogs and 
humans[24, 25, 63, 64] and activity levels have been shown to be species dependent. The rat 
possesses ≥14 times the aldose reductase activity compared to a dog and is also a species that 
readily develops cataracts relating to elevated blood sugar in the form of galactose.[26]  Dogs 
and humans show similar aldose reductase activity in the lens (0.39 nm/min/mg),[26] but the 
prevalence of cataracts with DM is higher in dogs, giving further weight to a multifactorial 
pathogenesis.[23]  Aldose reductase inhibitors applied topically to the ocular surface have been 
shown in the galactosemic dog model of DM to cause a dose-dependent reduction of cataract 
development but prevention of cataracts was not achieved with any concentration of the 
drug.[26]  More recently, a study evaluating effects of  a topically administered aldose reductase 
inhibitor, Kinostat
d
, applied to the eyes of 28 newly diagnosed diabetic dogs with naturally 
occurring DM showed delay the onset and progression of diabetic cataracts.  After 12 months, 
the cataract score in the treatment group was significantly lower than the control group, and 
cataract scores of the treatment group did not significantly increase from the time of 
enrollment.[65, 66] 
  
One study reported humans with Type 2 diabetes to have a 3.3% incidence of cataract formation 
over a 3.6 year observation period.[67]  A retrospective study evaluating information from two 
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major medical databases over 35 years reported that diabetic humans had a high risk (mean risk 
ratios ranging from 2.30-2.95) for developing cataracts, when compared to a reference 
cohort.[68]  The 10-year cumulative incidence of cataract surgery in diabetic humans was 8.3% 
and 24.9% in patients suffering from Type 1 and Type 2 diabetes, respectively.[69] Humans 
have higher sorbitol dehydrogenase activity compared to dogs, which converts sorbitol to 
fructose.[64]  Fructose is able to slowly diffuse through the lens capsule or it may reenter the 
glycolytic pathway for further metabolism.[25] This may be an explanation for the lower 
prevalence of diabetic cataracts in humans compared to dogs and other animals.[64] 
 
The prevalence of DM in cats is 1 in 50 to 1 in 400 depending on the population studied[7, 70] 
and generally occurs in cats greater than 7 years of age.[24]  Cataracts are not a common 
complication of DM in cats, as aldose reductase activity decreases with age and is significantly 
lower in adult cats.[24]  Lenses of dogs and cats that were incubated in a high glucose medium 
(30 mmol/L) for 14 days showed glucose-related lens changes (vacuole development and lens 
fiber swelling) in both species; glucose-induced lens alterations between dogs and cats differed 
in location and extent.  Dogs developed large vacuoles at the equator of the lens.  Lenses from 
cats ≤4 years old developed prominent suture lines from lens fiber swelling and extensive 
posterior cortical opacities with associated small vacuoles.  All lenses from young cats (≤ 4 years 
old) and no lenses from aged cats (10-18 years old) developed cataracts.[24] 
 
 Anatomic and Immunologic Considerations with Anterior Uveitis 
 Blood Aqueous Barrier  
Anatomically, the blood aqueous barrier (BAB) is composed of the posterior pigmented 
epithelium of the iris, the vascular endothelial cells of the iris, and the tight junctions between the 
non-pigmented ciliary body epithelial cells.[71]  The following inflammatory mediators are 
known to play a role in destabilization of the BAB: prostaglandins (PG), leukotrienes, platelet-
activating factor, neuropeptides like calcitonin gene-related peptide and substance P, nitrous 
oxide, bradykinin, and interleukins.[72]  Vascular permeability is increased, allowing larger, 
intravascular molecules (namely proteins) to pass between endothelial cells and enter the anterior 
chamber.  Prostaglandins are the main substances that result in the clinical manifestation of 
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intraocular inflammation.[73] Leukotrienes were shown to not be an important mediator of BAB 
disruption; leukotriene inhibitors may actually exacerbate disruption by shunting arachadonic 
acid (AA) toward the cyclooxygenase (COX) pathway.[74] 
 
 Phacolytic Uveitis or LIU  
As the osmotic pressure within the aqueous humor equilibrates across the lens capsule of a 
cataractous lens, soluble proteins (α, β-heavy, β-light, and γ-crystalline), which are antigenic, 
migrate from the lens.  Lens proteins released in small amounts are phagocytized by antigen 
presenting cells, which then exit the eye via the trabecular meshwork and travel to the spleen 
where afferent (CD4+) and efferent (CD8+) regulatory T cells are formed.  A scenario of anergy 
or immune tolerance in the eye is created by preventing activation and differentiation of naïve T 
cells (afferent phase) and suppression of Th1 immunity (the effector phase) of cell-mediated 
immune response.  This mechanism is accomplished through anterior chamber associated 
immune deviation.[75] Subsequent lens protein release follows an altered antigen presentation; 
CD8+ cells are activated, which suppress Th1-mediated, delayed-type hypersensitivity in the 
eye.  During excessive exposure of lens proteins in the anterior chamber, T-cell tolerance 
homeostasis is overwhelmed, and Th1 immunity is activated.[75]  Release of inflammatory 
cytokines results in compromised BAB integrity.  Protein leakage and leukocyte (monocyte) 
chemotaxis ensue.[76] This exaggerated, non-specific inflammatory response to translocated lens 
protein causing breakdown of the BAB is known as phacolytic or LIU.[33, 76, 77] The 
prevalence of LIU with any stage of cataract is reported to be 71%,[53] but subclinical uveitis 
may account for an even greater number affected.[78, 79] Histologically, phacolytic uveitis 
typically manifests as a mild lymphoplasmacytic uveitis, but a severe granulomatous anterior 
uveitis (macrophages, lymphocytes, and neutrophils) is possible associated with hypermature 
cataracts.[33, 76, 77] 
 
 Phacoclastic Uveitis 
Phacoclastic uveitis is an exaggerated inflammatory response of the eye following exposure to 
large volumes of lens proteins released with rupture of the lens capsule.[76, 77] Lens capsule 
rupture may occur spontaneously, secondary to rapid progression of diabetic cataracts in dogs or 
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by ocular trauma with direct damage to the lens capsule.[33, 77] Wilkie et al documented lens 
capsule ruptures in 9% (20/215) of diabetic dogs that received cataract surgery in a 6 year period. 
Cataracts in these dogs were noted to have been present for a significantly shorter duration (39 
days) than diabetic dogs without lens capsule rupture (mean 63 days).[33] Most ruptures 
occurred in the weaker, equatorial aspect of the capsule, approximately half of the dogs 
experienced this complication bilaterally, and the Labrador Retriever was over-represented (6/20 
dogs) for this finding.[33]  Light microscopy of globes diagnosed with phacoclastic uveitis 
shows intralenticular polymorphonuclear cells; it is characterized by zonal inflammation with a 
more chronic change being perilenticular fibroplasia and granulomatous uveitis.[77] 
 
 Clinical Signs of Anterior Uveitis 
A hallmark clinical sign of uveitis is aqueous flare, in which proteins in the aqueous humor are 
visualized with slit-lamp biomicroscopy.[80]  A phenomenon known as the Tyndall effect occurs 
when light from the slit-lamp is scattered as it contacts the proteins in the anterior chamber, 
creating a characteristic “fog” within the normally transparent aqueous humor.  The degree of 
aqueous flare appreciated is directly proportional to the severity of breakdown of the BAB.[72]  
Aqueous flare is quantified on a 0 to 4+ scale, and although the assignment is subjective, a 
common grading scheme is followed.  If aqueous flare is barely detectable, it is considered 1+, 
whereas 2+ is moderate, 3+ is typified by hazy detail of intraocular structures such as the iris and 
lens.  Intense flare with fibrin is classified as 4+, and would require the most aggressive 
treatment.  Intraocular structures are barely visible to totally obscured with this degree of 
inflammation.[81]   
 
Other consistent findings with uveitis are hypotony (decreased intraocular pressure), a miotic 
pupil, resistance to pharmacologic dilation, rubeosis iridis (a meshwork of small vessels on the 
iris surface), suspended cells in the anterior chamber, change in iris color, and keratic 
precipitates (accumulations of inflammatory cells that adhere to the corneal endothelium).  
Preiridal fibrovascular membranes may be identified histologically, which are termed rubiosis 
iridis clinically.[80]  The pathogenesis of its development is suspected to be due to hypoxia, 
angiogenic, and fibroblastic stimulatory factors associated with chronic inflammation.[82] 
Hyperemia of the conjunctiva or episcleral injection, ciliary flush (hyperemia of the 
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circumcorneal anterior ciliary vessels), photophobia, or other signs of ocular pain 
(blepharospasm, elevated third eyelid, pawing at the affected eye, or epiphora) can be observed 
concurrently but are not findings specific to uveitis.[80]   
 
 Treatment of Anterior Uveitis 
 Routes of Anti-inflammatory Drug Administration 
Topical anti-inflammatory medications are indicated for treatment of anterior segment 
inflammation, with the drug type and frequency based on severity of clinical disease.  
Medications applied topically penetrate to the level of the posterior lens capsule, making other 
routes of administration necessary for the treatment of posterior uveitis.[83, 84]  Ease of 
administration and the ability to minimize systemic side effects are two benefits of topical 
therapy.[85] One of the main disadvantages of topical administration involves the difficulty in 
penetrating the lipophilic corneal epithelium, which represents a major barrier to absorption of 
many medications.[84] The corneal epithelium and Descemet’s membrane are lipophilic, 
whereas the corneal stroma is hydrophilic.  Drugs with an intermediate solubility profile are 
better able to penetrate intact cornea than are drugs that are strictly lipophilic or hydrophilic.[83] 
Acetate and alcohol corticosteroid formulations, which are more lipophilic, show superior 
corneal penetration compared to phosphate formulations.[86] 
 
Subconjunctival administration of anti-inflammatory medications can achieve high 
concentrations in the anterior chamber and may be used concurrently with other therapeutic 
routes.[84] Administration in the bulbar subconjunctival space allows for use of hydrophilic 
drugs and affords improved efficiency, as the drugs do not have to pass through the conjunctival 
epithelium, a major rate-limiting step.  Drugs given by this route are absorbed directly through 
the cornea and sclera and into the anterior chamber, ciliary body, and vitreous.[87] Medications 
may also ooze from the injection site and bathe the cornea, from where they then penetrates, or 
they may be absorbed into the conjunctival blood vessels and return hematogenously to the uveal 
tract.[83]  Long-term therapy (8 hours to 2-3 weeks depending on formulation) via slow release 
of drug can be achieved,[83, 84] which is advantageous for the aggressive or feral dog or the 
poorly compliant owner.  Corticosteroids are commonly used anti-inflammatory medications 
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administered by subconjunctival injection.  Phosphate formulations are water soluble and 
therefore quickly absorbed from the injection site, but acetate and diacetate esters have a longer 
duration of action, as they are poorly water soluble.  Betamethasone, dexamethasone, 
methylprednisolone acetate, and triamcinolone acetonide are commercially available 
corticosteroids that may be administered subconjunctivally.[84] A disadvantage of a 
subconjunctival injection  is that the medication  cannot be discontinued if complications arise; 
topical anti-inflammatory medications should not be administered in the face of a corneal ulcer 
or corneal infection, as they reduce migration of neutrophils and macrophages, impair host 
defenses and increase the risk of or exacerbating infection.[84] Additionally, subconjunctival 
granulomas may form at the injection site that can serve as a chronic source of inflammation and 
may require surgical excision.[88] Subconjunctival administration of NSAIDs is not 
recommended, as it has been shown to cause severe inflammation at the injection site.[89]   
  
Systemic anti-inflammatory therapy is effective for treating anterior segment inflammation and 
may be selected for combined treatment with topical or subconjunctival corticosteroid 
therapy.[84]  When selecting this route and determining a dose, judicious use must be employed.  
Consideration should be given to underlying diseases that preclude treatment with systemic 
steroids (i.e., generalized infection, diabetes mellitus, pancreatitis, etc.) and adverse systemic 
side effects that occur with administration.[84]  
 
Intravitreal injections and sustained release dexamethasone intravitreal implants are rarely used 
in veterinary medicine but can treat posterior segment inflammation.[83, 84] Lens-induced 
uveitis causes inflammation primarily of the anterior segment, making these routes of 
administration less indicated.    
 
 Drug Properties and Available Ophthalmic Medications 
Treatment of uveitis is accomplished through the use of topical and systemic anti-inflammatory 
drugs, either steroidal or non-steroidal.[51, 73, 76-78, 83, 84, 89-94] (Figure 1.1)  
Corticosteroids bind intracytoplasmic receptors present in most tissues, which then translocate to 
the nucleus and modify gene transcription.[1, 95] The synthesis of lipocortins is increased, 
blocking phospholipase A2 and preventing conversion of phospholipids to arachidonic acid 
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(AA).[95]  Suppression of AA inhibits subsequent formation of PG, prostacyclin I2, 
thromboxane A2, and leukotrienes (LTD4, LTE4).[73, 84, 91] Corticosteroids may induce 
expression of somatostatin, which has been shown to elicit anti-inflammatory effects.[96]  
Glucocorticoids inhibit prostaglandin synthesis at the cyclooxygenase pathway; they also have 
been proposed to have lysosomal membrane stabilization properties, which would protect 
organelle membranes from lysis and leakage of cell contents.[84] 
 
Figure 1.1: Inflammatory Cascade and the Therapeutic Mechanism of Action 
 
Lightning bolts represent points of activation and red, slashed circles represent points at which steroids 
and NSAIDs inhibit the inflammatory cascade.  Figure created by Jane Ashley Stuckey and Mal Rooks 
Hoover, 2014. 
 
Available topical ophthalmic steroid preparations include: 0.12% and 1% prednisolone acetate, 
1% prednisolone sodium phosphate (available in combination with antibiotics), 0.1% 
dexamethasone alcohol, 0.1% dexamethasone sodium phosphate (available in combination with 
antibiotics) or 0.1% dexamethasone-cyclodextrin, and hydrocortisone acetate (available in 
combination with antibiotics).  As drugs used for local anti-inflammatory purposes do not 
undergo hepatic conversion to the active metabolite, prednisolone is required for topical 
ophthalmic use as opposed to prednisone, as the former is the metabolically active 
glucocorticoid.[1] The acetate and alcohol drug formulations are more lipophilic and therefore 
afford improved corneal penetration compared to the sodium salts of the phosphate formulation, 
which are water soluble.[84, 86] The cyclodextrin-based delivery system enhances the solubility 
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of dexamethasone in aqueous ophthalmic formulations and also improves permeability into the 
human eye, allowing aqueous humor drug concentrations to exceed those reported for other 
ophthalmic steroid medications.[97]  The drug generally accepted to be the most efficacious for 
treating anterior segment inflammation is 1% prednisolone acetate.[84] 
Additional FDA approved ophthalmic steroids less commonly used in veterinary medicine 
include: 0.05% difluprednate, 1% medrysone, 1% rimexolone, 0.1% and 0.25% fluorometholone 
alcohol, and 0.2% and 0.5% loteprednol etabonate.  The latter three drugs listed are considered 
“soft steroids.”  Soft steroids are selected for use with the goal of providing local anti-
inflammatory effects with a lower risk of inducing ocular hypertension in humans.[84, 95, 98]  
Loteprednol is a highly lipophilic, ester steroid that is metabolized to an inactive form in the 
aqueous humor, minimizing local side effects of ocular hypertension and cataractogenesis.[95] 
Humans receiving 0.5% loteprednol etabonate suspension 4 times daily to one eye showed more 
mild ocular hypertension (rise from 17.4 mmHg to 21.5 mmHg) after 42 days of treatment 
compared to those same individuals treated 4 times daily with 1% prednisolone acetate to one 
eye (rise from 18.1 mmHg to 27.1 mmHg) for 42 days.[85] The rise in intraocular pressure in the 
latter group was significant, lending merit to the study of and continued use of this drug in 
human medicine.[85] There are no reports on the efficacy of soft steroids or their use in 
veterinary medicine.  Ocular hypertension from ophthalmic steroid application is not a clinical 
concern in dogs, although it has been induced experimentally in Beagles with primary open 
angle glaucoma; intraocular pressure rose by a mean of 5 mmHg after two weeks of therapy with 
0.1% dexamethasone but returned to normal following cessation of the medication.[99] 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the conversion of AA to prostaglandins 
(PGE2, PGD2, PGF2α), prostacyclin (PGI2), and thromboxane A2 via inhibition of COX.[73, 84, 
91] Both the constitutive form (COX-1), which is expressed on the endoplasmic reticulum of all 
cells in the body, and the inducible form (COX-2), which is synthesized by macrophages and is 
seen with inflammation, are inhibited by NSAIDs.[73]  Efficacy of NSAIDs applied to the ocular 
surface in dogs has been thoroughly evaluated.[78, 91, 100-103]  Commonly used, commercially 
available ophthalmic NSAIDs include: 0.1% diclofenac sodium, 0.03% flurbiprofen, 0.09% 
bromfenac, 0.4% and 0.5% keterolac tromethamine, and 0.1% nepafenac.[73, 84, 104]  Suprofen 
and tolmetin in 1% formulations have been used in veterinary research.[100]  Indomethacin is an 
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ophthalmic NSAID commercially available in Europe and Canada.[73] Ophthalmic NSAIDs are 
indicated in the treatment of PG-induced inflammation post cataract surgery; they are also 
beneficial in preventing intraoperative inflammation and miosis during cataract surgery.[73, 84]  
 
 Experimental Use of Ophthalmic Anti-inflammatory Medications 
Topical anti-inflammatory medications are effective at preventing and/or controlling 
experimentally induced anterior uveitis in dogs.  Ward et al showed that 1% solutions of 
ophthalmic NSAIDs were effective (diclofenac >flurbiprofen>suprofen) at preventing 
breakdown of the BAB following anterior chamber paracentesis.[100]  Ward et al also performed 
a study comparing the efficacy of ophthalmic steroids and NSAIDs and their ability to inhibit 
paracentesis-induced anterior uveitis.  Results showed that 1% prednisolone acetate and 0.03% 
flurbiprofen were more effective than 0.1% dexamethasone sodium phosphate at stabilizing the 
BAB as determined by fluorophotometry.[101] Pilocarpine-induced anterior uveitis was 
documented to be inhibited by 0.03% flurbiprofen, 0.1% diclofenac, and 1 % suprofen, as 
quantified by laser flaremetry.  Non-steroidal anti-inflammatory drugs were more effective than 
topical 0.125 or 1% prednisolone acetate at inhibiting BAB breakdown induced by the 
antidromic stimulation from topical pilocarpine.[78] Millichamp and Dziezyc also showed that 
pretreatment with 0.03% flurbiprofen prevented signs of anterior uveitis following lens capsule 
disruption with neodymium:yttrium aluminum garnet laser.[102] 
 
In cats, topical application of 1% prednisolone acetate and 0.1% diclofenac were effective at 
reducing aqueous flare quantified by laser flaremetry when anterior uveitis was induced by 
anterior chamber paracentesis; 0.1% dexamethasone and 0.03% flurbiprofen did not significantly 
decrease flare at any time point.[91]  Topical application of 0.1% dexamethasone beloxil (AL-
2512) reportedly inhibited endotoxin-induced leukocyte influx in cats by 59% compared to 1% 
prednisolone acetate, which inhibited influx by 37%.[105] 
 
 Side Effects of Topical Ophthalmic Anti-inflammatory Medications 
Use of topical ophthalmic corticosteroids is contraindicated with corneal infection (bacterial, 
fungal, or viral), as therapy can exacerbate infection.[84] Corticosteroids decrease neutrophil and 
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macrophage migration and depress their phagocytic function.[106]  Epithelialization of a corneal 
ulcer can be delayed by the use of these drugs, and stromal keratocyte proliferation and collagen 
deposition are also reduced with steroid treatment.[84, 107]  Ocular hypertension occurs in 
normal and glaucomatous humans [85, 95] and normal cats[108] following use of topical 
ophthalmic steroids; this has also been shown experimentally in glaucomatous Beagles.[99] 
Steroid-induced cataract formation is a concern in humans.[95] This is not appreciated clinically 
in veterinary species,[84] yet steroid-induced cataracts have been experimentally produced in 
cats following topical administration of 0.1% dexamethasone sodium phosphate or 1% 
prednisolone acetate 2-3 times per day to 1 eye.[108] Lipid keratopathy is a clinically recognized 
condition noted in dogs following topical corticosteroid treatment.[84]   
 
Reported potential side effects of topical NSAID administration in dogs include local irritation 
(conjunctival hyperemia and mild burning sensation) and ocular hypertension.  These drugs are 
also contraindicated in cases of infectious keratitis.[73, 84]   
 
 Rationale for Treatment of LIU 
Treatment of intraocular inflammation is important to preserve vision and minimize pain and 
complications associated with LIU.[109]  Secondary glaucoma is a major complication of 
chronic uveitis that is not only a blinding condition but is also painful.[110-112] Intraocular 
inflammation causes alterations in the conventional aqueous humor outflow pathway. The 
iridocorneal angle can collapse or undergo fibrosis following chronic inflammation, or 
inflammatory cells and fibrin may obstruct the drainage angle.  Inflammatory membrane 
formation (preiridal fibrovascular membrane, cyclitic membrane, retrocorneal memebrane) may 
develop and occlude the pupil or iridocorneal angle.[82]  Posterior synechia, when the pupillary 
margin of the iris adheres to the anterior lens capsule, and peripheral anterior synechia, when the 
iris root adheres to the peripheral cornea, inhibit aqueous humor outflow.[80, 110] In a study 
evaluating different management plans for dogs with cataracts, failure (defined as painful, 
inflamed, or glaucomatous, and in the cases that received surgery, non-visual) occurred in 100% 
of untreated eyes (n=8 eyes [5 dogs]); the failure rate for dogs that received no treatment was 
64.5 times higher than in dogs receiving medical treatment (n=35 eyes [20 dogs]) and 255 times 
higher than in dogs receiving surgical treatment (n=34 eyes [19 dogs]).  The rate of failure for 
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dogs receiving medical treatment alone was 4.0 times higher than for dogs undergoing surgery.  
The time to failure for the no treatment group was significantly shorter than for the treatment 
groups, with reasons for failure being persistent uveitis and secondary glaucoma.  The anti-
inflammatory ophthalmic medications used in that study were not specified.[109] The population 
of dogs in the no treatment group was likely skewed to include dogs with noticeable ocular 
pathology or evidence of ocular pain, necessitating reevaluation, or potentially, to include dogs 
with secondary glaucoma and owners interested in a surgical procedure not typically performed 
in a general private practice setting (i.e., evisceration with placement of an intrascleral 
prosthesis).  
 
Treatment of LIU is recommended to prepare dogs for cataract surgery, in an effort to maximize 
the success of the procedure while also treating dogs for iatrogenic inflammation incited by 
surgery.[76, 113]  In a study of 151 dogs with LIU, 14% suffered complications due to 
uveitis;[90] eyes that underwent lens extraction and had a history of LIU had a lower long-term 
success rate, mainly due to glaucoma and phthisis bulbi.[90] Similar failures (glaucoma and 
phthisis bulbi) were documented in a retrospective study comparing the success rates of eyes 
with and without LIU; eyes that had a history of LIU had a reduced success rate (52%) 6 months 
following cataract surgery compared to eyes without a history of LIU (95%) at the same time 
point.[53] Miller et al also identified postoperative anterior uveitis as the main cause of failure or 
as causing complications in visual eyes following cataract surgery; the ophthalmic findings 
included glaucoma, severe anterior uveitis, retinal detachment, pupillary occlusion, posterior 
synechia and corneal edema.[114] However, one study suggested the presence of LIU prior to 
surgery was not associated with an increased risk of failure.[51]  Topical treatment with steroids 
and NSAIDs following cataract surgery may be required for months to maintain control of post-
operative uveitis.[33] 
 
 Systemic Absorption of Topically Applied Drugs 
After topical application of an ophthalmic medication, a portion of the medication will be 
absorbed systemically through the fenestrated blood vessels of the conjunctiva and episclera 
and/or nasal or oral mucosa after the medication passes through the nasolacrimal system. 
Ingestion of the drug and subsequent absorption is also possible if the dog licks the medication 
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from the nose after passage through the nasolacrimal duct or if drug enters the oropharynx, as 
dogs may have an accessory opening of the nasolacrimal duct in the oral cavity.  Some of the 
drug will be absorbed into the aqueous humor and enter systemic circulation following entry into 
the uveal vasculature or through the angular aqueous plexus.[83] Evidence of systemic 
absorption following ocular application of medications has been documented in rabbits and 
horses by identification of the drug in plasma, serum, and/or urine.[115, 116] Topically applied 
medications are able to bypass primary metabolism by the liver, as drugs placed on the corneal 
surface can be absorbed from the conjunctiva or nasolacrimal mucosa directly into the 
bloodstream.[83] 
 
Suppression of the hypothalamic-hypophyseal-adrenal axis has been documented in dogs via 
ACTH stimulation testing following application of topical 1% prednisolone acetate suspension 4 
times daily (mean dose of 4 mg/day) for two weeks[117, 118] and one study continued 
administration for two additional weeks at a reduced topical dose (mean dose of 2.67 mg/day).  
Two weeks after discontinuing steroid treatment, pre-ACTH stimulation cortisol levels returned 
to baseline, and ACTH stimulation responses returned to values that were within the normal 
response range (although they were still diminished by 26% compared to pretreatment 
levels).[118] Glucagon stimulation was also performed in this study, showing an exaggerated 
increase in BG with glucagon administration after 4 weeks of ophthalmic steroid treatment.[118]  
Adrenal suppression was confirmed in a group of healthy Beagles following topical application 
of 0.1% dexamethasone suspension four times daily to both eyes for 8 and 16 weeks (mean dose 
of 0.03 mg/kg of BW per day).  Histopathologic changes in the liver included vacuolated 
hepatocytes, increased hepatic glycogen content, and ballooning degeneration of 
hepatocytes.[119]  Subconjunctival administration of methyl-prednisolone acetate (10 mg dose 
repeated 21 days after initial administration) has caused similar effects in dogs.[120]  Murphy et 
al documented iatrogenic HAC in a Boston Terrier following 5 years of ophthalmic steroid 
treatment; clinical signs and ACTH stimulation results returned to normal following cessation of 
the topical steroid therapy.[121]  Topical application of ophthalmic 0.1% dexamethasone sodium 
phosphate has been demonstrated to significantly increase BG concentrations in diabetic humans 
undergoing cataract surgery.[104]  Another study in diabetic humans showed a significant 
increase in both the fasting BG values and HbA1C levels after treatment with topical ophthalmic 
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steroids for 3 and 7 weeks, respectively.  Patients included in the study did not receive a uniform 
steroid type (4 different ophthalmic medications) or dose frequency (range not listed).  As 
HbA1C is a molecule composed by glycation of hemoglobin, its level reflects the mean BG 
concentration over a period of 1 to 2 months prior to collection and indicated worsening of 
glycemic control of patients in this study.[122] 
 
Other studies report evidence of systemic absorption of topically applied medications in dogs.  A 
dilation protocol for 3 dogs prior to cataract surgery included 2.5% phenylephrine drops 
administered 6 times in the 1.5 hours before surgery for two dogs and 11 applications of 10% 
phenylephrine in the 3 hours before surgery in the remaining dog.  The excessive phenylephrine 
doses caused dogs to experience arterial hypertension, but it was medically controlled with 
acepromazine maleate.[123] Ophthalmic preparations of a beta-blocker, 0.5% timolol maleate, 
applied topically as a single dose to one eye was confirmed to decrease basal blood pressure and 
heart rate in dogs (mean ± standard deviation [SD] BW of 12.6±0.8 kg),[124] as well as lower 
the intraocular pressure (IOP) in the treated (mean of 16.1% reduction in IOP) and untreated 
(mean 9.0% reduction in IOP) eye of dogs; pupil size was also decreased in both eyes as a result 
of the drug.[125] 
 
Exploration of alternative routes of insulin administration lead researchers to consider 
ophthalmic application and whether systemic absorption could achieve a desired therapeutic 
effect.  Ophthalmic application of regular porcine insulin (administered with emulsants) in 8 
euglycemic dogs was shown to reduce serum glucose and increase serum insulin 
concentrations.[126] Similar findings were reported for the diabetic dog and hyperglycemic 





Chapter 2 - The Effects of Ophthalmic Prednisolone and Diclofenac 
on Diabetes Mellitus Regulation in Dogs 
 Introduction 
An issue of debate is whether topical ophthalmic steroids exacerbate insulin antagonism and 
interfere with glycemic control in diabetic dogs.[1] Currently, no studies have evaluated possible 
systemic effects of topical ophthalmic steroids in diabetic dogs.  Topical steroid and non-
steroidal anti-inflammatory medications are commonly used to treat LIU, as well as to prevent 
and control inflammation following cataract surgery. Cataract formation is the most common 
ocular complication of canine DM,[1, 20] and diabetic dogs constitute a large percentage of the 
dog population presented to veterinary ophthalmologists for cataract surgery.[33, 51]  Human 
diabetic patients undergoing cataract surgery who were treated post-operatively with a topical 
ophthalmic steroid (0.1% dexamethasone disodium phosphate) 4 times daily for one month 
experienced significantly increased fasting post-surgical BG concentrations compared to both 
pre-surgical concentrations and fasting post-surgical BG concentrations from diabetic patients 
that were instead treated with 0.1% diclofenac 4 times daily for one month.[104]  Fasting BG 
concentrations for steroid-treated patients rose from baseline mean ±SD of 170±55.5 mg/dL to 
229±76.8 mg/dL, which was significantly greater than the NSAID group that had a mean ±SD of 
198.4±66.5 mg/dL after one month of therapy.[104]  Treatment with topical ophthalmic steroids 
may produce similar effects in diabetic dogs.   
 
The objective of the study was to evaluate use of a topically applied ophthalmic steroid (1% 
prednisolone acetate ophthalmic suspension
e
) and a non-steroidal anti-inflammatory drug (0.1% 
diclofenac sodium ophthalmic solution
f
) on BG concentrations, serum fructosamine 
concentrations, and clinical scores in diabetic dogs with cataracts using descriptive analysis.  We 
hypothesized that 1% prednisolone acetate would negatively affect BG regulation in diabetic 
dogs.  Results of this study are expected to influence selection of topical anti-inflammatory 




 Materials and Methods 
 Study Design  
This is a prospective, randomized, double masked, experimental study involving two phases of 
data collection one month apart.  This study was approved by the Institutional Animal Care and 
Use Committee of Kansas State University (approval code #3078.1). 
 
 Power Analysis Calculations for Final Enrollment Number 
Power analysis calculations were conducted to determine the sample size needed to detect 
treatment effects on outcomes of interest, namely fructosamine concentrations, binary outcomes 
from the clinical score sheet, and weight loss.  All calculations were designed to grant ≥80% 
power with a Type I error rate of 5%.  Type I error is when the true null hypothesis is incorrectly 
rejected, resulting in a false positive determination; this would allow a conclusion to be made 
that does not actually exist.   
 
The range of fructosamine concentrations for well-controlled diabetic dogs was determined from 
Briggs et al[43] and divided by 4 to conduct an “empirical-rule based”[129] approximation of the 
residual SD.  A SD of 100 µmol/L was squared to obtain the variance for power calculation.  The 
data curves were plotted and the intersection of number of dogs (x-axis) that would grant desired 
power (y-axis) was recommended.  Results suggested >35 dogs would be needed to ensure >80% 
power to detect a 100 µmol/L difference in fructosamine concentrations between dogs of each 
treatment group.  The enrollment number was rounded up to 40 dogs, as a conservative number 
is more likely to reveal a clinical change in dogs when statistical significance is documented.  
Binary or dichotomous outcomes from the clinical score sheet (example, increase in water 
consumption, yes/no) were used to verify the 40 dog enrollment number by assuming a 50% and 
5% difference in proportion of clinical events over time for the 1% prednisolone acetate and 
0.1% diclofenac groups, respectively.  The 50% change (which was used for calculation) was 
more stringent compared to looking for a 40, 30, or 20% change in response for the 1% 
prednisolone acetate group; when a smaller % change was accepted, more dogs were needed to 
reveal significance in findings.  Enrollment number based on binary outcomes required >30 dogs 
to grant 80% power.  Finally, 5% weight loss from a baseline of 25 kg was selected according to 
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an anticipated weight loss range for diabetic dogs of 0-13%[43] or 0 to 3.25kg for a 25 kg dog.  
Again, the approximate SD was obtained (0.8 kg) by dividing by 4,[129] and this value was 
squared to provide a variance for power calculation.  Many more than 40 dogs would be required 
to find significance for a smaller % weight loss (such as 2.5%).  A total sample size of 15 dogs 
granted 90% power when evaluating for a 5% weight loss.  There was more power to detect 
treatment effects with weight loss than for any other variable considered; final enrollment 
number was selected based on the most power-constrained response of interest. 
 
 Animals 
Twelve client-owned dogs diagnosed with naturally-occurring, insulin-treated DM were enrolled 
in the study from October 2011 to March 2014, and descriptive analysis was performed on the 
data collected.  Diabetic dogs examined by the Kansas State University ophthalmology, internal 
medicine, or general pet health departments were considered for enrollment.  Flyers detailing the 
study objective and research design were distributed to local veterinary clinics within a 20 mile 
radius of the Veterinary Health Center (VHC) and were posted at continuing education 
conferences hosted on-site.  Owners of presumably controlled diabetic dogs were encouraged to 
contact an investigator (Dr. Jane Ashley Stuckey) to discuss history, clinical signs, possible 
enrollment, and details of the study.  
 
 Inclusion and Exclusion Criteria  
Inclusion criteria specified that 1) all dogs enrolled were diagnosed with DM, were receiving 
insulin therapy, and had achieved a status where they were each deemed “controlled” per history 
and PE, and 2) all dogs had cataracts.  The owners were questioned about clinical signs including 
PU, PD, PP, and weight loss (>5%) in the month prior to enrollment to help determine glycemic 
control.  Each dog was required to have an acceptable PE (as determined by Drs. Tom 
Schermerhorn or Kate KuKanich) for enrollment. Owners enrolling a dog in the study were 
required to be willing to administer therapy to each eye for one month while the dog was home 
and to commit to return for repeat diagnostic testing in exactly one month in order to obtain a 
complete data set.   
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Dogs were excluded if there was a change in insulin dose or if topical or systemic steroid or non-
steroidal anti-inflammatory medications had been administered within the past month.   When a 
concurrent endocrinopathy such as HAC was present, the dog was being treated for this 
condition and considered controlled prior to enrollment. Dogs were not enrolled if preliminary 
blood work showed major abnormalities that required medical care or if bacteriuria was present, 
as determined by a urine sediment exam. With regard to ocular exclusion criteria (following 
examination by Drs. Amy Rankin or Jessica Slack), no dog could have significant uveitis defined 
as >1+ aqueous flare (as immediate treatment would be indicated) or a corneal ulcer (as 
treatment with either drug would be contraindicated and likely amplify absorption of the drug, 
which would potentially alter the results). A trace amount of inflammation was accepted for 
enrollment, as dogs would receive a topical ophthalmic anti-inflammatory agent soon after 
examination (3 days later) as part of the study design.  
 
 Examinations and Clinical Score Assignment 
All dogs underwent an ophthalmic examination by a board certified ophthalmologist (Drs. Amy 
Rankin or Jessica Slack) and PE by a board certified internal medicine specialist (Drs. Tom 
Schermerhorn or Kate KuKanich) prior to inclusion (day 0).  The complete ophthalmic 




 and intraocular pressure 
measurement via rebound tonometry
i
 followed by slit lamp biomicroscopy
j
 and indirect 
ophthalmoscopy
k
 when cataracts did not preclude posterior segment examination.   
 
A complete history was obtained by an internal medicine specialist who also performed the PE 
on the dog.  Specific clinical signs and examination findings were documented on a clinical score 
sheet designed for this study.(Appendix B) Answers to questions on the scoring sheet were 
dichotomous (yes/no), allowing responses to be translated to numerical values (1/0) to obtain a 
cumulative score.  (An example of a question, outcome, and numerical assignment would be as 
follows: Increase in weight gain of >5% over the past month? Answer: yes; score for that 





 Diagnostic Testing 
A complete blood count (CBC), serum chemistry panel, and urinalysis were performed on day 0, 
prior to enrollment. (Figure 2.1) Once examinations and preliminary diagnostics confirmed 
candidacy for enrollment in the study, a serum fructosamine was submitted to Antech
l
 and the 
continuous glucose monitoring (CGM) device (Guardian
®
) was applied to the dog for up to 72 
hours (from day 0 up to day 3). The CGM sensors were placed in the dorsal subcutaneous tissue 
of the thorax, 1-3 inches lateral to midline.  Prior to placement, the haired skin was shaved and 
wiped with alcohol and allowed to air dry.  Sensors were secured in place using tissue glue 
and/or adhesive tape.  Phase 1 of the study was complete following removal of the CGM device; 
dogs returned home (day 3-31) to receive 4 weeks of the designated masked topical, ophthalmic 
anti-inflammatory medication administered by owners.   
 
 
CGM- continuous glucose monitoring; Hx- history; PE- physical exam; Rx mgmt- medical 
management; Sx- surgery.  The figure illustrates the study design.  There are two phases of 
hospitalization (day 0 up to day 3 and again from day 32 to 35).  Dogs returned home between testing 
(day 3-31) for owners to administer the assigned ophthalmic medication as instructed.  Figure created 
by Mal Rooks Hoover, 2014. 
 
Following the double-masked research design, the ophthalmic medications were rebottled (in 
identical 10 mL amber glass vials bottles with dropper squeeze tops) and labeled by the Kansas 
State University dispensary staff to read “Drug Red” or “Drug Blue”.  This prevented both 
Figure 2.1: Timeline for the Research Project 
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investigators and owners from knowing the medication assigned to each color code.  Owners 
were shown how to administer ophthalmic medications prior to each dog’s discharge from the 
hospital.  They were required to apply 1 drop of the designated topical ophthalmic anti-
inflammatory medication to both eyes 4 times daily for 4 weeks (days 3-31) and were asked to 
record daily administration on a provided medication log.  Insulin and all previously prescribed 
medications were continued during the 4 weeks of the study.  Owners were contacted weekly by 
an investigator (Dr. Jane Ashley Stuckey) to ensure compliance with administration of the study 
drug.  Dogs returned on day 32 for Phase 2, which included repeat history assessment, PE, 
ophthalmic examination, clinical score assignment, and all diagnostics (CBC, serum chemistry, 
urinalysis, serum fructosamine concentration), as well as continuous glucose monitoring for 24-
72 hours (days 32-35). Ocular anti-inflammatory therapy was continued during that time 
(administered by a veterinary student to prevent unmasking of the investigators). The data 
collection was complete following day 35. Continued topical ophthalmic anti-inflammatory 
treatment was recommended for all dogs following completion of the study. 
 
 Treatment groups 
Dogs were divided into two groups, assigned to receive either 1% prednisolone acetate 
ophthalmic suspension or 0.1% diclofenac ophthalmic solution.  Group assignments were made 
by categorizing dogs using a blocked randomization design stratified by sex, age (>10 years of 
age), and BW (>25 kg) followed by a coin toss to determine treatment group.  Blocked 
randomization is performed to control variability among factors not defined as outcomes of 
interest (i.e., age, sex, and BW).  Dogs are divided into subgroups (called blocks) such that 
variability within is less than variability between subgroups; dogs within blocks are then 
randomly assigned to treatments. A single investigator (Dr. Jane Ashley Stuckey) designated the 
group assignments and kept the information filed with all patient examination and test results. 
These drugs remain masked, to date, as research is still underway.  No dog received a placebo 
ophthalmic medication (to represent a control group) according to the construct of the study 
design; anti-inflammatory therapy in dogs with diabetic cataracts is standard of care and 
withholding this treatment was deemed unethical.  Topical anti-inflammatory medications are 
also prescribed to prepare dogs for cataract surgery, and it would be unethical to withhold anti-
inflammatory therapy prior to surgery.   
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 Data Analysis 
Descriptive analysis was performed on the data to date from 12 dogs to evaluate the following 
outcomes of interest: clinical scores, blood work and urinalysis findings, serum fructosamine 
concentrations, and recommendations for insulin dose adjustments (based solely on CGM 
results(.   
 
The following method was used to assess glucose curves.  Phase 1 and Phase 2 curves for 12 
dogs (n= 24 curves) were analyzed.  For curve analysis, identifiers for each dog were masked, 
group assignment per dog was not disclosed, and the curves were unpaired (i.e., 24 curves were 
randomly presented to evaluators).  Evaluators applied previously published criteria[44] to 
determine whether an insulin dose adjustment was indicated and, if so, whether the dose should 
be increased or decreased.  Decisions about insulin dose adjustments were made only by CGM 
curve analysis; no individual or clinical information was considered as part of curve evaluation.  
Each curve contained up to 72 hours of CGM data (3 consecutive 24-hr curves).  Curve 
evaluations were carried out using the average curve generated by the CGM software from all 
available data for each phase. Evaluators (Drs. Tom Schermerhorn and Kate KuKanich) 
separately analyzed each curve.  Recommendations from each evaluator were compared to 
determine agreement. Any disagreements were reconciled through discussion and the reconciled 
result recorded. 
 
When the study is complete and data have been collected for a total of 40 dogs, statistical 
analysis will be performed by an investigator (Dr. Nora Bello).  Generalized linear mixed models 
will be fitted to the responses of interest, namely serum fructosamine concentrations, glucose 
concentrations, and clinical scores.  These models will include fixed effects for treatment, breed 
and age, as well as the random effect of patient to account for any repeated observations within a 
dog. Where appropriate, model assumptions will be evaluated. Inflation of Type I error will be 





 Screening and Attempted Enrollment  
Although data collection for the study was from October 2011 to March 2014, coding for the 
Kansas State University VHC database was available through December 2013.  From October 
2011 to December 2013, 118 diabetic dogs were evaluated at the VHC, averaging 4.4 diabetic 
dogs examined per month.  Of those evaluated by the investigators and deemed candidates for 
enrollment, participation was declined by owners of 31 dogs, either due to distance of travel (n = 
3), unwillingness to be separated from the dog (n = 3), unwillingness to post-pone cataract 
surgery (n = 10), or were lost to follow up after initial evaluation (n = 15).  Twelve dogs had 
significant uveitis in one or both eyes and were started on topical anti-inflammatory medications 
at the initial ophthalmic examination.  Thirteen dogs had one or more ocular conditions that 
prevented enrollment (uncontrolled keratoconjunctivitis sicca, secondary glaucoma, deep corneal 
ulcer requiring conjunctival graft surgery, enucleation, and lens luxation), and four dogs had 
cataract surgery prior to October 2011.  Four of the 118 dogs were newly diagnosed with DM, 
and insulin therapy was initiated.  The remaining diabetic dogs required therapy for major 
systemic diseases (DKA, pancreatitis, pyelonephritis, etc.) or received soft tissue or orthopedic 
surgery. 
 
Five dogs failed initial diagnostic testing.  Three dogs were diagnosed with bacteriuria on the 
urine sediment exam.  The dogs were treated with oral antibiotics according to culture 
susceptibility results.  One dog was enrolled in the study following treatment and a negative 
urine sediment exam.  Another dog showed persistent bacteriuria, and the owner elected to not 
attempt future enrollment.  The final dog was sent home for systemic antibiotic treatment; 
following the antibiotic regimen, several unsuccessful attempts were made to contact the owner 
to schedule Phase 1 testing and enrollment.  Two dogs required medical treatment following 
evaluation of initial diagnostic tests; one dog had marked hypoalbuminemia and concurrent 
electrolyte imbalances, and the other dog showed persistent hypoglycemia with need for an 
insulin dose reduction.  The latter dog was enrolled approximately 6 weeks later following 




Two dogs did not complete the study due to owner-admitted inability to comply with 
commitments of the study design.  One owner requested to withdraw the dog from future testing 
for personal reasons unrelated to the study.  The other dog was eliminated from Phase 2 testing 
following a weekly phone call by an investigator (Dr. Jane Ashley Stuckey), as the owner 
described being unable to administer the ophthalmic medication to the dog due to aggression 
displayed with application. 
 
 Animals Enrolled 
Twelve diabetic dogs have been enrolled in the study.  The study population consisted of 7 
spayed females and 5 castrated males.  Breeds represented include 3 Cairn Terriers and one each 
of the following: Beagle, Miniature Poodle, Pembroke Welch Corgi, Rat Terrier, Border Collie, 
Miniature Schnauzer, Chihuahua, Australian Shepherd, and a mixed breed dog.  Ages ranged 
from 5-13 years with a mean ±SD age of 8.9±2.3 years.  The mean ±SD population BW was 
15.68±7.35 (range of 4.2-28.0 kg) and 15.81±7.68 (range of 4.0-28.3) for Phase 1 and Phase 2, 
respectively. 
 
Hospitalization during CGM data collection was performed in 10/12 dogs.  Dogs were 
hospitalized for a mean ±SD of 57.79±7.56 hours (range of 50 to 74 hours) for diagnostic testing.  
While hospitalized for Phase 1 testing, 1 dog (Drug Red group) was inadvertently under-dosed 
with insulin for the first 2 treatments.  This was corrected for all subsequent doses administered 
to this dog.  Two dogs were monitored as outpatients, meaning the CGM device was worn while 
under the owners’ care and observation.  Those 2 dogs were evaluated in hospital every 12 hours 
during Phase 1 and 2 of data collection, and the glucose monitoring system was calibrated at 
those intervals.    
 
Dogs had the following concurrent disease conditions: HAC (n=1), neoplasia (n=1, mast cell 
tumor), protein-losing nephropathy (n=4), arthritis (n=3), food allergy (n=1), evidence of 
bacteriuria upon return for Phase 2 as diagnosed by the urine sediment exam (n=3), perivulvar 
dermatitis (n = 1), and severe dental disease (n=1).  The dog with HAC was diagnosed and 




 Group Demographics 
Drug Red group had a mean ±SD age and BW of 9.3±1.8 years (range of 6-11 years) and 
15.51±9.46 kg (range of 4.1-28.15 kg), respectively. Two male/castrated and 4 female/spayed 
dogs were in this group.  Drug Blue group had a mean ±SD age and BW of 8.5±2.9 years (range 
of 5-13 years) and 15.97±5.86 kg (range of 10.75-26.15 kg), respectively.  Drug Blue group 
included 3 male/castrated and 3 female/spayed dogs. The mean ±SD insulin dose recommended 
for all dogs was 0.83±0.28 u/kg (range of 0.36-1.41 u/kg), with dogs from Drug Red receiving a 
mean ±SD dose of 0.69±0.20 u/kg (range of 0.36-0.91u/kg) and dogs from Drug Blue receiving a 
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 and 1 dog 





 History, Physical, and Ocular Examinations 
Upon return for Phase 2 testing, 1 owner reported PU/PD as a newly observed clinical sign 
exhibited by the dog; this dog was in the Drug Red group.  Two owners reported witnessing 
clinical signs of hypoglycemia (one from each treatment group), one of which treated for this by 
administering Karo syrup
p
 to the dog’s gingiva (Drug Red group). 
 
Physical examination findings were fairly consistent between Phase 1 and Phase 2 for all dogs.  
Nine of 12 dogs were considered over-conditioned (body condition score ≥4 out of 5) according 
to the examiners (Drs. Tom Schermerhorn or Kate KuKanich).  Weight loss was documented in 
5 of 12 dogs (42%); however, no dog lost more than 5% BW from Phase 1 to Phase 2 of the 
study.  Of the 5 dogs that lost weight, 2 dogs were in Drug Red group and 3 dogs were in Drug 
Blue. 
 
Ocular examination showed a single dog to have very mild uveitis at Phase 1, manifested as trace 
aqueous flare in both eyes (OU); evidence of uveitis was not appreciated in this dog at Phase 2.  
A different dog had uveitis (manifested as keratic precipitates and resistance to pharmacologic 
dilation) in the left eye (OS) at the Phase 2 ocular examination. Ocular hypertension (right eye 
(OD): 16 mmHg, OS: 25 mmHg) was present OS in 1 dog at Phase 1 examination, and was 





 OU every 8 hours prior to cataract surgery, at which time bilateral 
anteriorly luxated lenses were observed and intracapsular lens extractions were performed OU.  
These 3 dogs were assigned to the Drug Blue group.  Cataract stages for all dogs (24 eyes) at 
Phase 1 examination were as follows: 8 immature, 14 mature, and 2 hypermature cataracts.  
Cataract stages for all dogs (24 eyes) at Phase 2 examination were: 8 immature, 12 mature, and 4 
hypermature cataracts.  Cataract progression was documented in two dogs (4 eyes) from Phase 1 
to Phase 2; both dogs were assigned to the Drug Blue group.  One dog had mature cataracts at 
Phase 1 that progressed to hypermature over the study period; this dog was the one that exhibited 
uveitis in the left eye at the Phase 2 examination. The other dog with cataract progression 
showed increased lens opacification from Phase 1 to Phase 2 examination, as the fundus was 
difficult to visualize only at the second examination; the cataracts were classified as immature at 
both time points.  One dog exhibited retinal hemorrhages in the right eye at both examinations, 
which were attributed to diabetic retinopathy after mean blood pressure (140 mmHg) and blood 
work evaluation (platelet count = 332,000 K/uL).  No corneal ulcers were diagnosed.  Mean ±SD 
Schirmer tear test values for Phase 1 and 2 were 19.42±3.74 mm/min OD, 18.50±4.23 mm/min 
OS and 19.67±4.62 mm/min OD, 19.75±2.70 mm/min OS, respectively.  Schirmer tear test 
values ranged from 12-28 mm/min in Phase 1 and 9-27 mm/min in Phase 2.  Mean ±SD 
intraocular pressures for Phase 1 and 2 were 7.92±4.38 mmHg OD, 8±5.97 mmHg OS and 
7.67±7.83 mmHg OD, 9.25±10.46 mmHg OS, respectively.  Intraocular pressures ranged from 
3-25 mmHg in Phase 1 and 3-42 mmHg in Phase 2.  A total of 8 dogs had cataract surgery 
following Phase 2 of the study.   
  
 Clinical Score 
Using the clinical score sheet (Appendix B), dichotomous outcomes of interest were documented 
for each dog.  Clinical scores for all dogs from Phase 1 and Phase 2 had a mean of 2.1 and 2.2, 
respectively, which represented a 1 point total increase over time.   
 
When comparing drug groups, the direction of change was similar.  In both groups, 2 dogs 
showed an improvement in clinical score (reduced numerical value over time), 2 showed no 
change from Phase 1 to Phase 2, and 2 had a worsened clinical score.  The Drug Red group 
showed a 17% increase in mean clinical score over time (Phase 1 mean=1.5; Phase 2 mean=1.8), 
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which equaled a total group score increase of 2 points.  The Drug Blue group’s mean score 
decreased by 7% (Phase 1 mean=2.7; Phase 2 mean=2.5), which equaled a total group score 
decrease of 1 point. 
 
 Complete Blood Count, Serum Chemistry, and Urinalysis 
Lymphopenia was observed on the CBC of 9 dogs (3 from the Drug Red group, 6 from the Drug 
Blue group) in Phase 1 and 8 dogs (4 per drug group) in Phase 2.  The mean ±SD lymphopenic 
counts for Phase 1 and Phase 2 measured 1.03±0.28 K/uL (normal range: 1.5-5 K/uL) and 
0.84±0.33 K/uL, respectively.  
 
An elevated  ALP was documented in 11 dogs in Phase 1 (range of high values: 203-2867 U/L 
[normal range: 1-142 U/L]) and in 10 dogs in Phase 2 (range of high values: 309-2724 U/L).  An 
increase in ALP (mean ±SD of increase between testing: 420.86±318.67 U/L; range of increase 
between testing: 154-1069 U/L) from Phase 1 to Phase 2 occurred in 7 dogs, 5 of which were in 
the Drug Red group and 2 of which were in the Drug Blue group.  The ALT was elevated (383 
and 404 U/L [normal range: 28-171 U/L]) in 2 dogs at Phase 1 testing.  Phase 2 testing revealed 
a rise ALT in 3 dogs (1 dog previously documented with an elevated ALT and 2 additional dogs) 
during the treatment period, all of which were in the Drug Red group. The range of elevated 
ALT values for Phase 2 was 237-588 U/L with a mean ±SD increase from Phase 1 to Phase 2 of 
166.67±39 U/L.  Cholesterol mean ±SD values for Phase 1 were 531.75±238.01 mg/dL and 
501.17±272.67 mg/dL for Phase 2.  Hypercholesterolemia was documented in 10 dogs (range of 
elevated values from 316-1185 mg/dL [normal: 133-394 mg/dL]) and 7 dogs (range of 434-1259 
mg/dL) in Phase 1 and 2, respectively; however, none of dogs were fasted prior to blood 
sampling.  The highest degree of lipemia (denoted as mild, moderate, or marked) recorded per 
dog was as follows: 1 with no comment on lipemia, 5 mild, 4 moderate, and 2 dogs were 
reported to have marked lipemia. 
 
Bacteriuria, diagnosed via urine sediment examination, was observed in 3 dogs in Phase 2 
urinalyses, 1 from the Drug Red group and 2 from the Drug Blue group.  Crystaluria (calcium 
oxylate [n = 1], struvite [n = 1], and amorphous [n = 4]) was noted in 6 dogs, with only one dog 
having crystaluria (amorphous) at the time bacteriuria was also visualized.  Urine specific gravity 
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ranged from 1.008-1.060.  Changes (an increase or decrease) in the degree of glucosuria and 





testing intervals were similar; both were documented to change in 6 dogs.  Glucosuria increased 
in 4 dogs (2 dogs per treatment group) and decreased in 2 dogs (1 dog per treatment group).  The 
maximum increase and decrease of glucosuria on the urine dipstick were +3 and -3, respectively.  
Proteinuria increased in 2 dogs (1 dog per treatment group) and decreased in 4 dogs (2 dogs per 
treatment group).  The maximum increase and decrease of proteinuria on the urine dipstick were 
+1 and -2, respectively.  One dog was diagnosed with +3 ketonuria (also reported on a 0 to +3 
scale on the urine dipstick) during Phase 2 testing.   
 
 Serum Fructosamine Concentrations 
Serum fructosamine concentrations ranged from 293-609 µmol/L with a mean ±SD of 
466±88.40 µmol/L for Phase 1.  Phase 2 values ranged from 390-714 µmol/L with a mean ±SD 
of 529±110.0 µmol/L.  Eleven of 12 dogs exhibited an increase in serum fructosamine 
concentrations (increased by mean ±SD of 75.82±64.03 µmol/L; range of 5-221 µmol/L) 
between testing intervals.  When comparing serum fructosamine concentrations over time 
between groups (Table 2.1), the Drug Red group showed a mean ±SD increase from 433±75.20 
to 516±104.18 µmol/L (mean of 16% increase), and the Drug Blue group showed a mean ±SD 
increase from 499± 94.60 to 543±124.30 µmol/L (mean of 8% increase).  
 
A serum fructosamine concentration  >450 µmol/L was defined as “unacceptable” on the clinical 
score sheet; values ≤450 µmol/L were “acceptable”.  Five dogs had acceptable serum 
fructosamine concentrations at Phase 1 (3 in the Drug Red group, 2 in the Drug Blue group), and 




Table 2.1: Serum Fructosamine Concentration Data per Group 
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Mean ±SD serum fructosamine concentrations from Phase 1 and Phase 2, the % increase in mean 
fructosamine concentrations over time, and the number of “acceptable” dichotomous outcomes 
assigned (defined as a serum fructosamine concentration ≤450 µmol/L) per phase are compared 
between Drug Red and Drug Blue groups.   
  
 Continuous Glucose Monitoring  
Sensors were in place a mean ±SD of 52.58±11.96 hours (Phase 1 mean ±SD: 47.92±12.6 hours; 
Phase 2 mean ±SD: 57.25±9.63 hours).  In general, CGM sensors were well-tolerated by dogs.  
One dog in the Drug Blue group, however, pulled or scratched the CGM sensor out of the skin 
consecutively at Phase 1 despite intervention (tissue glue, tape, and an Elizabethan collar).  A 
standard BG curve was performed in lieu of CGM, with peripheral venous blood samples 
obtained every two hours for the remainder of hospitalization.  A single glucometer (Accu-chek 
Complete
®s
) was used for the BG curve and BG calibrations to minimize variability between 





The figure represents the curves generated by the CGM device.  The sensor was placed around 1:00pm 
on 1/20/12 (blue line).  There are breaks at the peak of the curve; the CGM is unable to record values 
>400 mg/d.  The curve peaks around 7:00pm, which is the scheduled feeding and insulin 
administration time for this dog.  The waveform reappears around 8:00pm and declines to the nadir. 
The curve to represent subsequent days is demarcated by color (blue, green, red, purple). The dotted 
line represents the average recording from all days, used by two investigators to interpret CGM results 
for insulin dose adjustment recommendations.  
 
 Continuous Glucose Curve Evaluation 
Of the 24 curves evaluated, 22 curves received a recommendation on insulin dosing. (Table 2.2) 
Two curves from Phase 1 (1 curve per drug group) could not be interpreted and were excluded. 
One excluded curve was from the dog (Drug Red assignment) that was initially under-dosed with 
insulin, as this would falsely increase all concentrations of glucose recorded by the CGM device 
during the inappropriate treatment time and affect the overall average tracing, which was used to 
determine dosing recommendations.  The other excluded curve was from the dog (Drug Blue 
assignment) that received CGM and a standard BG curve, as an overall average tracing formed 
by the CGM device was not available for the standardized interpretation utilized in this study.   
 
No dose change was recommended for 5 of 22 curves (4 assigned to Drug Red, 1 assigned to 
Drug Blue).  Only one dog was determined to need no change in insulin dose at Phase 1; this dog 
Figure 2.2: CGM Curve (Dog 1, Phase 2) 
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was assigned to the Drug Red group.  Dose change was recommended for 17 of 22 curves. When 
a dose change was recommended, a dose increase was recommended for 12 curves (5 Drug Red, 
7 Drug Blue), and a dose decrease was recommended for 5 curves (2 Drug Red, 3 Drug Blue).  
Dose increases were typically recommended because curves violated the criteria for 12-hr post 
insulin injection glucose concentrations (>180 mg/dl).  The nadir value was outside of the 
desired range for most of these curves, as well.  Dose decreases were typically recommended 
because curves showed nadirs that were unacceptably low (<90 mg/dl).   When looking at 
change within each dog over time, the recommendations were the same for Phase 1 and 2 in 6/10 
dogs; recommendations differed over time for 4/10 dogs.  No dog was recommended to have no 
change for both phases.  
 
 Agreement between Evaluators 
Evaluators’ (Drs. Tom Schermerhorn and Kate KuKanich) recommendations were in agreement 
for 19/22 curves.  All three disagreements were the result of one evaluator recommending a need 
for a dose change and the other recommending no dose change.  Discussion between evaluators 
lead to an agreement of no dose change for these three dogs, as it more closely fit evaluation by 
Fleeman et al.[44] For all curves for which a recommendation of dose change was given, there 





Table 2.2: Insulin Dose Recommendations 
 
No. Phase 1 Phase 2 Drug 
1 Increase Increase Blue 
2 Decrease Decrease Blue 
3 Increase No Change Red 
4 Increase Increase Red 
5 Decrease No Change Blue 
6 Decrease Decrease Red 
7 Increase Increase Blue 
8 Increase Increase Blue 
9 No Change Increase Red 
10 Increase No Change Red 
11 EXCLUDED No Change Red 
12 EXCLUDED Increase Blue 
 
Dog enrollment number is recorded in column 1.  Recommendations for insulin dose adjustment from 
Phase 1 and Phase 2 are listed for each dog in column 2 and 3, respectively, along with group 
assignment in the last column.  
 
 
 Ophthalmic Medications and Dose Administered 
Medication logs were returned by all owners at Phase 2.  From day 3 to 31, owners were 
responsible for administering 112 treatments (4 times daily for 28 days) per eye for each dog.  
When treatments were missed, the medication was not administered to either eye; the number of 
documented missed treatments per dog ranged from 0 to 11 (mean ±SD of 4±3.98 times).  Only 
4 owners reported 100% adherence to the treatment regimen, and 1 owner reported a single 
missed treatment.  All other owners had ≥4 missed treatments. One owner recorded 11 missed 
treatments, which would equate to 90% adherence to the requested treatment regimen.  
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 1% Prednisolone Acetate Ophthalmic Suspension  
As 1% prednisolone acetate is formulated to 10 mg/mL, 100 mg of drug are contained within 
each 10 mL bottle.  The amber dropper bottle used in the study dispensed a total of 180 drops.  
The number of drops held per bottle was determined by an investigator (Dr. Jane Ashley 
Stuckey), who filled the 10 mL vials and counted the number of drops emitted. This was 
performed using 3 different bottles to verify a uniform number of drops dispensed. Considering 
each drop contained 0.56 mg (100 mg/180 drops) of the steroid and 8 drops were administered 
per day (4 times per day to both eyes), dogs received approximately 4.48 mg/day of 1% 
prednisolone acetate topically. The minimum and maximum BWs recorded for either phase were 
4.0 kg and 28.3 kg; using these body weights, the potential maximum dose was 1.12 mg/kg/day 
(if the lightest dog were assigned to this treatment), and the potential minimum dose was 0.16 
mg/kg/day (if the heaviest dog were assigned to this treatment) of 1% prednisolone acetate 
applied topically. 
 
 0.1% Diclofenac Ophthalmic Solution  
As 0.1% diclofenac is formulated to 1 mg/mL, 10 mg of drug are contained within each 10 mL 
bottle.  Considering each drop contained 0.056 mg (10 mg/180 drops) of the NSAID and 8 drops 
were administered per day (4 times per day to both eyes), dogs received approximately 0.45 
mg/day of 0.1% diclofenac topically.   Using the minimum and maximum body weights recorded 
from either phase, the potential maximum dose was 0.11 mg/kg/day (if the lightest dog were 
assigned to this treatment), and the potential minimum dose was 0.02 mg/kg/day (if the heaviest 
dog were assigned to this treatment) of 0.1% diclofenac applied topically. 
 
 Discussion 
Results of the descriptive analysis for the study reported here suggest a difference in several 
outcomes of interest between data from diabetic dogs treated with a topical ophthalmic steroid 
compared to a topical ophthalmic NSAID.  Preliminary descriptive analysis shows that dogs in 
the Drug Red group compared to those in Drug Blue showed a slight increase in the mean 
clinical score over time and more often showed a rise in ALP and ALT from Phase 1 to 2.  
Serum fructosamine concentrations rose in the majority of dogs (11/12) over time; the mean 
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serum fructosamine concentration per drug group increased by a larger percentage for the Drug 
Red group compared to the Drug Blue group.  Insulin dose adjustments were recommended for 
17/22 CGM curves from both Phase 1 and 2; insulin dose increases were recommended in 12 
dogs (5 from Drug Red and 7 from Drug Blue).  One owner reported observing signs of a dog 
assigned to the Drug Red group to become PU/PD during the treatment period; 2 dogs were 
reported to exhibit clinical signs of a hypoglycemic episode (one from each treatment group). 
 
 Concurrent Disease Conditions and Relevant Examination Findings 
Concurrent disease conditions present in several dogs should be mentioned, as neoplasia (n=1), 
HAC (n=1), and concurrent bacteriuria (n=3), which may indicate an occult urinary tract 
infection, can all complicate diabetic regulation.[17, 38, 42] These diseases are known to cause 
insulin resistance. No dog in the study received an insulin dose above 1.5 U/kg, which is a dose 
suggested to be associated with insulin resistance.[42] The mean ±SD insulin dose was 
0.83±0.28 u/kg (range of 0.35-1.42 U/kg).   
 
One dog had mild LIU in both eyes at Phase 1 examination that was controlled at Phase 2 
examination. A single dog had evidence of LIU in the left eye only at the Phase 2 examination, 
manifested as keratic precipitates and resistance to pharmacologic dilation. This overall good 
response to treatment (controlled inflammation in 23/24 eyes) indicates that the topical 
medications assigned were effective at treating and controlling LIU.   
 
 Clinical Score 
Mean clinical score rose slightly over one month (from 2.1 to 2.2); when the means were 
calculated per group, this increase was a result of the Drug Red group.  Although a change was 




 Diagnostic Testing 
 Serum Chemistry and Urinalysis 
Serum chemistry analysis from dogs in this study showed elevated liver enzymes to be a 
common abnormal finding, which was also reported in a large retrospective study of diabetic 
dogs.[17]  Alanine transaminase P5P is a liver specific cytosolic, leakage enzyme that indicates 
hepatocellular injury and necrosis.  Alkaline phosphatase is a production enzyme of the liver, but 
elevation is not specific to pathology of this organ system.  Two enzymes contribute to serum 
ALP in dogs: liver (L-ALP) and corticosteroid-induced isoenzyme (C-ALP).[1]  Diabetic dogs 
can show elevations in both ALT and ALP, but these findings may be an effect of another 
disease process or from administration of corticosteroids or NSAIDs.[17]  Cholestasis, chronic 
hepatitis, corticosteroid-induced hepatopathy, hepatic necrosis, and hepatic nodular regeneration 
(seen in older dogs) all cause elevations in ALP.[130]  In this study, 11 dogs had an elevated 
ALP and 2 dogs had an elevated ALT at Phase 1, which is best explained by the dogs’ systemic 
disease(s).  Further elevations in these 2 enzymes over the treatment period may represent 
exacerbation of the underlying disease or may be due to the assigned ophthalmic medication. 
The fact that 5/7 dogs and 3/3 dogs that showed a rise in ALP and ALT, respectively, were in the 
Drug Red group lends merit to the possibility that these changes may be related to the medication 
administered. 
 
Three dogs were documented with bacteriuria via urine sediment examination during Phase 2 
testing.  In other studies, 21-24% of diabetic dogs evaluated had an occult urinary tract infection 
with bacteriuria that was not always accompanied by pyuria,[17, 38] which is similar to the 25% 
(3/12) documented in our study.   
 
 Serum Fructosamine Concentrations and CGM Data 
Serum fructosamine concentration rose between Phase 1 and Phase 2 in 11 dogs.  Only 5 dogs 
had serum fructosamine concentrations that were defined as acceptable in Phase 1, and 4 
fructosamine concentrations were defined as acceptable in Phase 2.  When an increase in dose 
was recommended (12/22 curves) based on CGM analysis, serum fructosamine was defined as 
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unacceptable for 9 of those respective time points.(Table 2.3) This occurred in 3 dogs assigned to 
the Drug Red group and 6 dogs in the Drug Blue group.  Only once was no change in insulin 
dose recommended in a dog that was also determined to have an acceptable serum fructosamine 
concentration. All dogs recommended to have an insulin dose decrease were recorded as having 
acceptable serum fructosamine concentrations.  These findings suggest good agreement between 
the recommendations to increase the insulin dose based on a high (unacceptable) fructosamine 
concentration but the importance of further evaluating a dog with a fructosamine concentration 
≤450 µmol/L (acceptable) by another testing method to better determine BG control.  
 
Table 2.3: Comparison of Dichotomous Outcomes between Serum Fructosamine and CGM 
Data Interpretation for Change in Insulin Dose  
 
No. Phase 1 Acceptable or 
Unacceptable 
Phase 2 Acceptable or 
Unacceptable 
Drug 
1 Increase U Increase U Blue 
2 Decrease A Decrease A Blue 
3 Increase U No Change U Red 
4 Increase A Increase A Red 
5 Decrease A No Change A Blue 
6 Decrease A Decrease A Red 
7 Increase U Increase U Blue 
8 Increase U Increase U Blue 
9 No Change U Increase U Red 
10 Increase A No Change U Red 
11 OMIT U No Change U Red 
12 OMIT U Increase U Blue 
 
A- acceptable; U- Unacceptable. Phase 1 and Phase 2 recommendations for insulin dose adjustment 
compared to dichotomous outcomes of serum fructosamine concentration for each dog. Note, dog 10 





 1% Prednisolone Acetate and 0.1% Diclofenac 
Compared to other ocular steroids, 1% prednisolone acetate is considered the most effective anti-
inflammatory drug for treatment of inflammation in the anterior segment.[84, 101]  Studies have 
shown that 0.1% diclofenac exhibits superior efficacy compared to flurbiprofen in preventing 
inflammation following experimentally induced breakdown of the BAB in dogs.[100]  Both 
drugs are commercially available, experimentally proven to be effective methods of treatment, 
and are commonly prescribed by the investigators of this study with good clinical response to 
treatment, explaining why each was chosen to represent the ophthalmic steroid and NSAID used 
for comparison of outcomes. 
 
Dogs received approximately 4.48 mg/day of 1% prednisolone acetate or 0.45 mg/day of 0.1% 
diclofenac topically, which equates to a potential dose range of 0.16 to 1.12 mg/kg/day for the 
steroid or 0.02 to 0.11 mg/kg/day for the NSAID, depending on BW and group assignment.  
Exogenous steroid administration (similar to the mechanism with endogenous glucocorticoid 
release) causes insulin resistance.[1, 15, 42]  If the dog weighing the fewest kilograms were 
assigned to the steroid treatment, this dog would receive the high end of the steroid anti-
inflammatory dosage range (0.5-1 mg/kg/day).[130]  If the dog weighting the most kilograms 
were assigned to the steroid treatment, this dog would receive a dose less than that typically 
considered to represent physiologic supplementation.[130]  The degree of inflammation in the 
eye and the efficacy of individual medications determine treatment recommendations (drug type 
and frequency applied).[84] It is important to remember that a low BW can lead to a larger total 




Results of the preliminary descriptive analysis for the study reported here suggest a difference in 
several outcomes of interest between data from diabetic dogs treated with a topical ophthalmic 
steroid compared to a topical ophthalmic NSAID.  Preliminary descriptive analysis shows that 
dogs in the Drug Red group compared to those in Drug Blue showed a slight increase in the 
mean clinical score over time and more often showed a rise in ALP and ALT from Phase 1 to 2.  
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Serum fructosamine concentrations rose in the majority of dogs (11/12) over time; the mean 
serum fructosamine concentration per drug group increased by a larger percentage for the Drug 
Red group compared to the Drug Blue group.  Insulin dose changes were recommended for 
17/22 curves from both Phase 1 and 2; insulin dose increases were recommended in 12 dogs (5 
from Drug Red and 7 from Drug Blue).  When an increase in dose was recommended, serum 
fructosamine was defined as unacceptable for 9 of those respective time points. This occurred in 
3 dogs assigned to the Drug Red group and 6 dogs in the Drug Blue group.  An insulin dose 
decrease was recommended for 5 curves.  Interestingly, all dogs recommended to need an insulin 
dose decrease were evaluated to have acceptable fructosamine concentrations.  One dog (Drug 
Red group) was reported to exhibit PU/PD during the treatment period; 2 dogs were reportedly 




Chapter 3 -  Analysis of Study Design 
 Introduction 
A collaborative study between the ophthalmology and internal medicine services at Kansas State 
University was undertaken to determine whether topical ophthalmic application of a steroid can 
affect BG regulation in diabetic dogs.  Diabetes mellitus is a common endocrinopathy in dogs,[1] 
and diabetic cataracts occur as the most frequent ocular complication of DM in dogs.  Dogs with 
cataracts require ocular anti-inflammatory treatment to prevent and control LIU.[1, 20, 23]  
Information gleaned from this study will be a valuable contribution to the literature.  Reports of 
systemic effects in dogs following topical application of steroids exist,[117-121] and reports 
from human medicine regarding systemic effects of topical steroids in diabetic patients are 
available.[104, 122]  To the author’s knowledge, no study in the veterinary literature evaluates 
the use of topical, ophthalmic anti-inflammatory medications in diabetic dogs and the effects of 
those medications on diabetic regulation.   
 
 Diabetic Dogs Eligible for Enrollment 
 Recruitment of Dogs 
On average, 4.4 diabetic dogs are examined per month at the Kansas State University VHC.  
While this number of dogs should afford an adequate population for enrollment during the study 
period, diabetic dogs often visit a referral institution to address a current problem (for example: 
significant LIU, pancreatitis, DKA, etc.) and return to the primary veterinarian for routine care, 
making it more of a challenge to find dogs that fit enrollment criteria.  Of the dogs with well-
controlled DM , evidence of bacteriuria was the most common finding with initial diagnostic 
testing to preclude enrollment.  Occult urinary tract infections are diagnosed in approximately 
21-24% of diabetic dogs.[17, 38]  Urinary tract infections contribute to insulin resistance and 
may alter glycemic control,[17, 38] potentially complicating data interpretation. 
 
The population of diabetic dogs from surrounding areas seemed to be the most logical pool from 
which to draw, as distance of travel and extra visits to the hospital were deterrents to 
participation in the study according to some owners.  Flyers were designed to detail study 
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objectives and benefits of enrollment.  They were distributed to veterinary clinics within a 20 
mile radius of the VHC and were made available at continuing education conferences hosted on-
site.  Discussion of the study between referring veterinarians and investigators was also 
performed during phone consultations.   
 
 Resistance of Owners to Permit Participation 
Many dogs were presented to the ophthalmology service for the purpose of evaluation prior to 
scheduling phacoemulsification.  Enrollment made the possible date for cataract surgery a 
minimum of one month following examination.  Ten owners were anxious to have the procedure 
performed as soon as possible and declined study participation.  As enrollment in the study often 
committed owners to a minimum of one additional transit to and from the hospital and a large 
portion of owners travel from >2 hours away, this occasionally negatively affected willingness to 
participate (3 owners).  Three owners declined participation of a dog due to resistance to be 
separated from the dog or the belief that the dog would be stressed in a hospital environment.  At 
home monitoring with twice daily visits for calibration of the CGM monitoring device was 
offered to all owners.  Interestingly, the frequency of 4 times per day topical treatment was not 
reported to deter any owner from participation.  Study diagnostics, examinations, hospitalization, 
and one month’s treatment with an ocular anti-inflammatory medication were provided at no cost 
to owners, and information was relayed to primary veterinarians for continued care following 
conclusion of data gathering.  Despite these benefits, additional incentives may have encouraged 
more owners to grant participation.   
 
 Details of Study Design 
 Clinical Score Sheet Rationale 
No single test can be used to estimate the degree of glycemic control in diabetic dogs.  Multiple 
tests exist to quantify BG control (BG curve, serum fructosamine concentration, glycolated 
hemoglobin, CGM, urine glucose quantification), which emphasizes this point.  History, 
reduction in clinical signs of PU, PD, PP, and PE findings are often considered the most reliable 
method to judge BG control.[43]  Determining control is strategic and many pieces of 
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information factor into assessment.  The clinical score sheet was specifically designed for this 
study as a way to incorporate multiple evaluation points for interpretation (history, PE findings, 
ocular exam findings, fructosamine concentrations, and assessment of CGM data).  The score 
sheet allowed each question to be translated to a dichotomous outcome in order to derive a 
cumulative numerical value.  Some dogs have BG curves with a poor curve shape or a nadir 
higher than what the veterinarian would prefer in order to consider the dog well-controlled; 
however, the dog may no longer display PU, PD, PP, and has a stable BW.  These dogs would be 
considered clinically controlled.  The cumulative clinical score has the potential to represent 
clinical diabetic control, as it combines clinical signs with diagnostic test results.  The score was 
used to identify change within a dog over time (Phase 1 to Phase 2) and to compare between 
scores of dogs assigned to each drug group.   
 
 At Home Care of Dogs (Day 3-31) 
Client-owned dogs were enrolled in the study.  Following collection of Phase 1 data, dogs 
returned home for continued care until return to the hospital on Day 32.  Dogs in a familiar 
environment experience lower stress, and test results would more likely reflect the dogs’ actual 
degree of BG control when dogs remain in the owners’ care with only a single variable changed 
(introduction of a new topical ophthalmic medication administered 4 times daily).   Conversely, 
the ideal research setting would be to have a single investigator administer all medications to 
ensure accurate and timely application of the study drug.  When study participants are under the 
care of investigators, adherence to individual diet recommendations (not offering extra treats or 
table food that could affect daily glycemic control), standardization with exercise, and 
observance of a routine treatment schedule for administering the assigned medication are 
feasible.  It was not possible to offer this service for the 4 week length of the study period. 
 
 Rational of the Ophthalmic Anti-inflammatory Treatment Regimen 
Compared to the use of other topical ophthalmic steroids and NSAIDs for prevention and control 
of LIU in dogs, 1% prednisolone acetate and 0.1% diclofenac were shown to be the most 
effective.[100, 101]  Both drugs are commercially available and are commonly prescribed by the 
investigators of this study with good clinical response to treatment, explaining why each 
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medication was chosen to represent a steroid and NSAID treatment group.  The treatment 
frequency of 4 times per day to both eyes was practical to evaluate, as it reflects a common post-
cataract surgery protocol recommended for dogs[53] or a treatment regimen that may be required 
during times of active LIU.  Other studies evaluating systemic absorption of topically applied 
steroids have also employed a 4 times daily frequency.[117-119] 
 
 Limitations 
Limitations of the study include the lack of a placebo or control treatment group, the lack of a 
single objective measure of glycemic control, challenges associated with use of the CGM in 
dogs, and the potential for client compliance issues.  No untreated control group was assigned, as 
it would be unethical to administer a placebo or withhold medication in a dog that presents to the 
ophthalmology service with diabetic cataracts.  Most dogs with cataracts will have some degree 
of either subclinical or mild LIU.[53] Topical anti-inflammatory medications are prescribed to 
prepare dogs for cataract surgery, and it would be unethical to withhold anti-inflammatory 
therapy prior to surgery. Prophylactic treatment with anti-inflammatory agents is the minimum 
accepted standard for dogs diagnosed with cataracts.[20, 84, 109]  
 
There is no single objective measure to assess glycemic control, which is an inherent challenge 
of the management of DM in dogs. Blood glucose concentrations are affected by many variables 
including stress, inappetence, variability in the amount of insulin administered and absorbed 
from the injection site (particularly if different anatomic regions are used), and concurrent 
infections or illnesses.[1, 38, 42, 44]  Only CGM curves were used to define insulin dose 
adjustments (increase, decrease, or no change in insulin dose).  This was purposeful, however, to 
minimize subjectivity in this decision.  In order better interpret glycemic control, aside from 
CGM analysis, several parameters (serum fructosamine concentrations, clinical scores, and 
history, PE, and ocular examination findings) were measured and evaluated.  
 
Continuous glucose monitoring devices have inherent complications.  Securing them under the 
skin of dogs can be challenging, as they are designed for placement in humans.  Sensors were 
placed with the catheter in the subcutaneous tissue of the dorsolateral thorax, but most dogs 
enrolled in the study were over-conditioned, and subcutaneous fat in this area sometimes caused 
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folding of the skin, dislodging the sensor.  Data could be missed for a variable length of time if 
displacement occurred overnight.  Strategies were enforced to help ensure security of placement, 
including tissue glue, body tape, and having dogs wear stockingettes or Elizabethan collars.  
Sensors were well-tolerated among 11/12 dogs, but one dog removed multiple sensors despite 
intervention.  Calibration times were fixed and dependent on time of sensor placement, making 
consideration of timing especially important for owners of dogs not hospitalized that reported to 
the hospital every 12 hours for calibration of the CGM device. CGM devices must also be kept 
within 6 feet of dogs at all times during data collection.  The CGM sensor is only capable of 
recording glucose concentrations >40 or <400 mg/dL.  While these extremes still represent 
significant times of hypoglycemia or hyperglycemia, respectively, the incomplete data limits 
interpretation. 
 
Potential for problems relating to owner compliance with administration of topical medications is 
also a limitation of the study.  While the maximum number of reported non-treatment times out 
of the 112 requested treatment times was 11, this still represents 90% adherence to the outlined 
treatment regimen.  Only 4 owners (representing 1/3 of the dogs enrolled in the study) reported 
having no missed treatments during the study period.  All owners of the dogs enrolled in the 
study were considered compliant with treatment requests, as a 90% treatment cutoff was 
accepted.  This does assume that medications were actually applied when dosing was 
documented on the medication log.  In order to minimize problems with compliance issues, an 
investigator (Dr. Jane Ashley Stuckey) taught owners how to administer the ophthalmic 
medication properly, giving strategies for unassisted administration.  Owners were sent home 
with a medication log to record times of application, and they were called weekly to discuss the 
medication schedule and dog tolerance of topical ophthalmic treatment.  Phone calls were 
effective in eliminating one owner with poor compliance from completing the study. 
 
 Critique of the Study Design 
 Revising the Clinical Score Sheet  
The clinical score sheet could be refined to enable the cumulative score to be a more reliable 
indicator of clinical glycemic control.  Some dichotomous outcomes were assigned by surveying 
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the dog’s owner.  Eight of the 15 questions on the clinical score sheet require a response from the 
owner; 7/15 are assigned by investigators that perform the PE and evaluate the CGM data (Drs. 
Tom Schermerhorn or Kate KuKanich) or perform the ocular exams (Drs. Amy Rankin or 
Jessica Slack).  Answers from survey questions are at risk of inherent subjectivity and bias.  For 
example, owners may be poorly educated on the signs of hypoglycemia but asked to speak on 
whether a dog displayed clinical signs of this metabolic state.  Owners may remark that PU, PD, 
and PP have subsided when, in fact, the signs have improved but are still inappropriately 
increased.  Bias may be introduced, as owners subconsciously want physical and monetary 
efforts (in veterinary visits, husbandry, and insulin administration) to be effective at 
appropriately managing the dog’s DM.  Some owners may attribute a reduced activity level to 
cataract development and associated visual compromise when the question was designed to 
assess a manifestation of metabolic imbalance and poor BG control.  An example of how a 
question could be rephrased would be that instead of asking if there has been a change in water 
consumption, ask if the owner has had to refill the water bowl more frequently within the last 
month (or since Phase 1 evaluation). Or, instead of asking about a change in activity level, 
phrasing the question, “Have you noticed a decrease in the dog’s activity, which you feel is 
unrelated to changes vision?”   
 
Also, it is possible that some outcome measures on the clinical score sheet were made too 
stringent, namely the serum fructosamine concentration and CGM analysis (determining 
recommendations on insulin dose adjustment).  Another study found well-controlled dogs to 
have a fructosamine concentration <525 µmol/L;[43] however, the definition of an unacceptable 
fructosamine concentration in this study was >450 µmol/L.  This more strict definition of an 
acceptable outcome may have raised clinical scores by 1 point in dogs that were actually well-
controlled.  In order to standardize analysis of CGM data and recommendations on insulin dose 
adjustment between investigators (Drs. Tom Schermerhorn and Kate KuKanich) and between 
dogs, a published guideline[44] for interpretation was followed.  Many clinicians would still 
consider a curve that was slightly elevated from that defined in the guideline to represent that of 
a controlled diabetic dog.  It would be interesting to also evaluate curves by calling them 
“clinically acceptable or unacceptable.” Ultimately, the decision to increase or decrease insulin 




All of the questions on the clinical score sheet relate to glycemic control with the exception of 
the outcome regarding owner compliance, which refers to compliance with insulin administration 
and application of the dispensed ophthalmic medication. While this is good information to 
document, assigning a point for poor compliance of the owner would increase the dog’s 
cumulative clinical score.  Poor compliance with insulin administration would absolutely 
contribute to loss of glycemic control.  Poor compliance with application of the dispensed 
ophthalmic medication would mean that less of the medication was available for systemic 
absorption and likely have even less of an effect on glycemic control.  Revising the score sheet to 
not assign a numerical value to this outcome (making the total equal 14 points) would allow only 
outcomes directly associated with the dog (not the owner) to be tallied.  
 
 Length of the Study Period 
Considering a 2 weeks study period as opposed to 4 weeks, may encourage additional owners to 
consent to participation. Other studies[117, 118] have shown effects of topical ophthalmic 
steroid treatment after two weeks of 4 times daily application to both eyes, suggesting this 
timeline may be reasonable to assess outcome measures in our study.  To counter the possibility 
of reduced effects, the frequency of anti-inflammatory therapy could be increased slightly, likely 
at the expense of owner compliance.   
 
 Conclusions 
Achieving diabetic control in dogs is challenging, but assessment of control is also difficult and 
requires consideration of many variables and test results.  For this reason, the study faces 
obstacles that are nearly unavoidable.  The study design was carefully constructed to maximize 
ability to assess control, and power analysis followed a conservative approach to ensure that 
when statistics are performed, significant changes, when found, would more likely represent a 
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Appendix A - Normal Lens Glucose Metabolism 
 
Aqueous humor resembles an ultra filtrate of plasma.  Several of the organic and inorganic 
compounds normally present in the aqueous humor are displayed.  Glucose undergoes passive 
diffusion or facilitated transport through the semi-permeable lens capsule, and under physiologic 
conditions (a euglycemic state), the glucose metabolism pathways are exhibited with their respective 
percentage of glucose processed. Figure created by Mal Rooks Hoover, 2014. 
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Appendix B - The Effects of Ophthalmic Prednisolone and 
Diclofenac on DM Regulation Evaluation of Diabetes Control 
Patient History 
Need for insulin adjustment in previous 4 weeks Yes 
      No 
 
Change in water consumption   Yes-increased water consumption 
      No 
 
Change in urine frequency/amount   Yes 
      No 
 
Change in appetite/food intake   Change in appetite (increased) 
      No change in appetite 
 
Change in activity level    Change in activity level (decreased) 
      No change in activity level 
 
Signs of hypoglycemia noticed   Yes 
      No 
 
Required treatment for hypoglycemia  Yes 
      No 
 
Noncompliant with insulin/ocular medications Yes 
      No 
 
Physical Examination 
Change body weight  >5%    Yes  
      No 
 
Body condition score    Unacceptable (poor body condition) 
      Acceptable (good body condition) 
 
Hydration status     Dehydrated 
      Normal hydration 
 
Progression of cataract     Progression 
      No progression 
 
Uveitis present     Yes 
      No 
 
Laboratory Evaluations 
Fructosamine concentration   Unacceptable (>450 µl/L)     
      Acceptable (< 450 µl/L) 
 
Glucose curve analysis: insulin adjustment  Yes 
      No 
 
